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Abstract 
The Wnt/β-catenin signaling pathway is critical to embryonic development and adult 
tissue homeostasis.  Mutations to Wnt signaling components can cause dysregulation of the 
pathway, leading to various human diseases such as cancer.  The partially disordered protein 
Chibby (Cby) is a conserved nuclear protein that acts as an antagonist in the Wnt/β-catenin 
signaling pathway.  Cby’s antagonism is accomplished via two mechanisms.  First, by 
competing with the Tcf/Lef family of transcription factors, Cby abrogates the β-catenin-
mediated transcription of Wnt signaling genes.  Moreover, upon phosphorylation on serine 
20 by the kinase Akt, Cby forms a complex with the protein 14-3-3 to facilitate the nuclear 
export of β-catenin.   Structurally, Cby is composed of an unstructured N-terminal half, while 
its C-terminal half harbours a coiled-coil domain.  Cby’s N-terminal half comprises a 14-3-3 
binding motif, while its C-terminal half mediates the interaction with β-catenin, as well as 
TC-1, an antagonist of Cby.  In this thesis, the molecular details of Cby’s structural elements 
and its interactions with the Wnt signaling components 14-3-3, β-catenin and TC-1 were 
investigated.  The Cby/14-3-3 interaction was studied by using a combined approach of 
nuclear magnetic resonance (NMR) spectroscopy, isothermal titration calorimetry (ITC) and 
X-ray crystallography.  While the solved crystal structure revealed a canonical 14-3-3 
binding mode, NMR spectroscopy and ITC revealed that residues flanking Cby’s 14-3-3 
binding motif are involved in the interaction.  Next, hydrogen-deuterium exchange mass 
spectrometry revealed that in addition to Cby’s disordered N-terminus, Cby contains a 
disordered C-terminal extension. ITC and NMR experiments demonstrate that the disordered 
N-terminus negatively regulates target binding between TC-1 and Cby’s coiled-coil domain.  
Lastly, mutagenesis studies suggest that Cby’s coiled-coil domain utilizes differing binding 
modes when interacting with β-catenin and TC-1, with Cby binding as a monomer to β-
catenin and as a dimer to TC-1.  In conclusion, this thesis demonstrates how Cby’s structural 
 iii 
 
elements collectively mediate protein-protein interactions in the Wnt signaling pathway.  
 
Keywords 
Chibby; 14-3-3; β-catenin; TC-1; Wnt signaling pathway; coiled-coil; protein-protein 
interactions; phosphorylation;  X-ray crystallography; NMR spectroscopy; isothermal 
titration calorimetry; circular dichroism spectroscopy 
 iv 
 
Co-Authorship Statement 
Chapter 1 - Figure 1.1 is adapted from Clevers H, Nusse R (2012) Cell 149: 1192-1205.  
Figure 1.7 is adapted from Gall C, Xu H, Brickenden A, Ai X, Choy WY (2007) Protein 
Science 16: 2510-2518. 
 
Chapter 2 - This chapter contains an expanded version of the published manuscript Ryan C. 
Killoran, Jingsong Fan, Daiwen Yang, Brian H. Shilton and Wing-Yiu Choy Plos One 10(4): 
e0123934.  J. Fan and D. Yang collected NMR data required for NMR backbone assignment 
data on 14-3-3ΔC12 construct.  B.H. Shilton performed X-ray crystallography data collection 
and assisted with solving the 14-3-3/Chibby crystal structure.  Cα distance matrices used to 
calculate distance-based RMSDs in Figure 2.4 were generated by W.Y. Choy.  Susanna 
George assisted with protein purifications and isothermal titration calorimetry experiments 
involving all 14-3-3 isoforms.  All other experiments, ITC, NMR backbone assignment and 
titrations were conducted and analyzed by R.C. Killoran.  Manuscript was written by R.C. 
Killoran, B.H. Shilton and W.Y. Choy. 
 
Chapter 3 - This chapter contains an expanded version of the published manuscript Ryan C. 
Killoran, Modupeola A. Sowole, Mohammad A. Halim, Lars Konermann and Wing-Yiu 
Choy Protein Science. doi:10.1002/pro.2936 (ahead of print).  M. A. Sowole performed 
hydrogen-deuterium exchange mass spectrometry (HDX-MS) experiments, analyzed the 
HDX-MS data and designed Figure 3.1 and Figure 3.2.  M.A. Halim performed preliminary 
HDX-MS experiments on Chibby.  R.C. Killoran performed all other experiments involving 
 v 
 
circular dichroism and NMR spectroscopy and their analysis.  The initial manuscript was 
written by R.C. Killoran, followed by revisions from L. Konermann and W.Y. Choy.   
 
Chapter 4 - Figure 4.1 is adapted from Mokhtarzada S, Yu C, Brickenden A, Choy WY 
(2011) Biochemistry 50: 715-726. Cameron Harper assisted in the mutagenesis of the C-Cby 
L84A/L98A construct and helped develop the purification protocol of this mutant.  All 
circular dichroism and NMR spectroscopy experiments were performed and analyzed by 
R.C. Killoran. 
 vi 
 
Dedication 
 
 
For my parents, Liane and Calvin Killoran,  
and in memory of my grandparents, Annette and Leo Lauzon. 
 
 
 
 
 
 
 
 
 vii 
 
Acknowledgments 
I would like to thank my supervisor, Dr. James Wing-Yiu Choy, for his support and 
insight throughout my studies.  I feel very fortunate to have started in the Choy lab as a 
summer student during my undergraduate degree in 2010 and have continually enjoyed 
working under Dr. Choy’s supervision. 
To my advisory committee, Dr. Gary Shaw and Dr. Brian Shilton, thank you for your 
guidance and constructive suggestions. 
Thanks to members of the Choy lab, past and present, for your thoughtful discussions.  
Special thanks to our lab technician, Anne Brickenden, for going above and beyond everyday 
to help us grad students.    
I would like to thank Lee-Ann Briere for teaching and advising me on several 
biophysical techniques.  To members of the department, past and present, thanks for making 
my time here so enjoyable. 
To my partner Chelsea and to my parents, thanks for the love and support throughout 
this journey.  
 
 
 
 
 viii 
 
Table of Contents 
Abstract ............................................................................................................................... ii	  
Co-Authorship Statement................................................................................................... iv	  
Dedication .......................................................................................................................... vi	  
Acknowledgments............................................................................................................. vii	  
Table of Contents............................................................................................................. viii	  
List of Tables .................................................................................................................... xii	  
List of Figures .................................................................................................................. xiii	  
List of Abbreviations ....................................................................................................... xvi	  
Chapter 1............................................................................................................................. 1	  
1	   Introduction .................................................................................................................... 1	  
1.1	   Introduction to Wnt Signaling ................................................................................ 1	  
1.2	   Wnt/β-catenin signaling in human disease and therapeutic development .............. 5	  
1.3	   Regulation of  β-catenin in Wnt signaling.............................................................. 7	  
1.4	   The Wnt signaling antagonist Chibby..................................................................... 8	  
1.5	   Structural features and characterization of Cby.................................................... 13	  
1.6	   Structure of β-catenin and modes of interaction with Wnt signaling components16	  
1.7	   Structure, function and binding modes of 14-3-3 proteins ................................... 19	  
1.8	   The Cby antagonist TC-1...................................................................................... 23	  
1.9	   Scope of thesis ...................................................................................................... 25	  
1.10	  	  References............................................................................................................ 28	  
Chapter 2........................................................................................................................... 36	  
2	   Structural Analysis of the 14-3-3ζ/Chibby Interaction Involved in Wnt/β-catenin 
Signaling ...................................................................................................................... 36	  
2.1	   Introduction........................................................................................................... 36	  
2.2	   Materials and Methods.......................................................................................... 40	  
 ix 
 
2.2.1	   Expression and Purification of 14-3-3ζ .................................................... 40	  
2.2.2	   Peptide Synthesis ...................................................................................... 41	  
2.2.3	   Crystallization and Structure Determination ............................................ 41	  
2.2.4	   NMR Experiments .................................................................................... 42	  
2.2.5	   Isothermal Titration Calorimetry (ITC) Experiments............................... 42	  
2.2.6	   Accession Numbers .................................................................................. 43	  
2.3	   Results................................................................................................................... 44	  
2.3.1	   Phosphorylation of serine 20 on Cby is critical for its binding to 14-3-3ζ 
................................................................................................................... 44	  
2.3.2	   Flanking residues of the consensus 14-3-3 binding motif play important 
roles in the Cby/14-3-3ζ association......................................................... 45	  
2.3.3	   Molecular basis of the interaction between 14-3-3ζ and the non-canonical 
mode II binding-motif of Cby................................................................... 49	  
2.3.4	   An S22P mutation to Cby enhances its interaction to 14-3-3ζ ................. 52	  
2.3.5	   Probe for secondary interactions between 14-3-3ζ and Cby using NMR 
spectroscopy.............................................................................................. 56	  
2.3.6	   Mapping the Cby peptides binding regions on 14-3-3ζΔC12 .................. 62	  
2.3.7	   Cby binds to all human 14-3-3 isoforms................................................... 68	  
2.3.8	   14-3-3 phosphomimetic mutations fail to abrogate the 14-3-3/Cby 18-mer 
interaction ................................................................................................. 68	  
2.4	   Discussion ............................................................................................................. 72	  
2.5	   Acknowledgements............................................................................................... 78	  
2.6	   References............................................................................................................. 79	  
Chapter 3........................................................................................................................... 84	  
3	   Conformational characterization of the intrinsically disordered protein Chibby: 
Interplay between structural elements in target recognition ........................................ 84	  
3.1	   Introduction........................................................................................................... 84	  
3.2	   Materials and Methods.......................................................................................... 87	  
 x 
 
3.2.1	   Protein Expression and Purification.......................................................... 87	  
3.2.2	   Peptide Synthesis ...................................................................................... 88	  
3.2.3	   Hydrogen/Deuterium Exchange – Mass Spectrometry............................. 88	  
3.2.4	   Circular Dichroism Spectropolarimetry.................................................... 88	  
3.2.5	   NMR Spectroscopy................................................................................... 89	  
3.2.6	   Isothermal Titration Calorimetry (ITC) .................................................... 89	  
3.3	   Results................................................................................................................... 90	  
3.3.1	   Identifying the coiled-coil region of Cby using HDX-MS ....................... 90	  
3.3.2	   The disordered N-terminal half and C-terminal extension of Cby ........... 94	  
3.3.3	   Disordered regions of Cby tune its binding affinity to TC-1.................. 101	  
3.4	   Discussion ........................................................................................................... 107	  
3.5	   Acknowledgements............................................................................................. 110	  
3.6	   References........................................................................................................... 110	  
Chapter 4......................................................................................................................... 114	  
4	   Cby’s coiled-coil domain: Differing binding modes to TC-1 and β-catenin ............. 114	  
4.1	   Introduction......................................................................................................... 114	  
4.2	   Materials and Methods........................................................................................ 119	  
4.2.1	   Mutagenesis, Expression and Purification of Recombinant Proteins ..... 119	  
4.2.2	   Circular Dichroism Spectropolarimetry.................................................. 120	  
4.2.3	   Pull-down Assays ................................................................................... 121	  
4.2.4	   NMR Spectroscopy................................................................................. 121	  
4.2.5	   Peptide Synthesis .................................................................................... 122	  
4.2.6	   Isothermal Titration Calorimetry ............................................................ 122	  
4.3	   Results................................................................................................................. 123	  
4.3.1	   Design of Cby coiled-coil mutants and their effect on the protein’s 
stability.................................................................................................... 123	  
 xi 
 
4.3.2	   Interactions between TC-1 and Cby mutants.......................................... 128	  
4.3.3	   Structural analysis and stability of mutations to the coiled-coil of Cby in 
constructs lacking the disordered N-terminus......................................... 130	  
4.3.4	   Cby’s Interaction with β-catenin ............................................................ 134	  
4.4	   Discussion ........................................................................................................... 139	  
4.5	   References........................................................................................................... 142	  
Chapter 5......................................................................................................................... 145	  
5	   Summary and Perspectives ........................................................................................ 145	  
5.1	   Characterizing the Cby/14-3-3 Interaction ......................................................... 146	  
5.2	   Elucidating the structural elements of Cby and their interplay in target recognition
 147	  
5.3	   Differing binding modes for the Cby/TC-1 and Cby/β-catenin complexes ....... 148	  
5.4	   Future Directions and Perspectives..................................................................... 149	  
5.4.1	   Characterizing the 14-3-3/Cby interaction in the context of full-length Cby
................................................................................................................. 149	  
5.4.2	   Cby’s Disordered Ends Modulate Target Binding.................................. 150	  
5.4.3	   Monomeric Cby and its interaction with β-catenin ................................ 151	  
5.5	   Conclusion .......................................................................................................... 152	  
5.6	   References........................................................................................................... 153	  
Curriculum Vitae........................................................................................................ 155	  
 xii 
 
List of Tables 
Table 2.1 Thermodynamic parameters of phosphorylated Cby peptides to 14-3-3................ 46	  
Table 2.2 Duplicate set of thermodynamic parameters for the binding of phosphorylated Cby 
peptides to 14-3-3ζ.................................................................................................................. 47	  
Table 2.3 Crystallographic data collection and refinement statistics ..................................... 50	  
Table 2.4 Thermodynamic parameters of Cby 18-mer binding to all 14-3-3 isoforms.......... 69	  
Table 2.5 Duplicate thermodynamic parameters for the binding of Cby 18-mer to 14-3-3 
isoforms .................................................................................................................................. 69	  
Table 4.1 Deconvoluted CD spectra of full-length Cby and C-terminal Cby coiled-coil 
mutants.................................................................................................................................. 126	  
 
 xiii 
 
List of Figures 
Figure 1.1 Wnt signaling models .............................................................................................. 4	  
Figure 1.2 Cby Multiple Sequence Alignment ......................................................................... 9	  
Figure 1.3 Cby in Wnt Signaling ............................................................................................ 12	  
Figure 1.4 Cby's coiled-coil domain ....................................................................................... 15	  
Figure 1.5 Structure of β-catenin and its binding partners ..................................................... 18	  
Figure 1.6 14-3-3 Sequence, Structure and its Canonical Binding Mode .............................. 22	  
Figure 1.7 Previous TC-1 NMR Studies................................................................................. 24	  
Figure 1.8 The Cby/14-3-3/β-catenin Tripartite Complex...................................................... 27	  
Figure 2.1 ITC thermograms with unphosphorylated Cby peptides....................................... 44	  
Figure 2.2 ITC thermograms for various phosphorylated WT and mutant Cby peptides 
titrated into 14-3-3ζ................................................................................................................. 48	  
Figure 2.3 Crystal structure of the 14-3-3ζ/Cby 18-mer complex.......................................... 51	  
Figure 2.4 Structural comparison of 14-3-3ζ-bound Cby with other 14-3-3 binding motifs 
comprising various +2 residues .............................................................................................. 53	  
Figure 2.5 A comparison of the orientation of 14-3-3ζ's K49 side-chain in the 14-3-3ζ/Cby 
and 14-3-3ζ/Raf1 (PDB: 3CU8) complexes ........................................................................... 55	  
Figure 2.6 14-3-3ζ K49A ITC thermograms .......................................................................... 56	  
Figure 2.7 1H-15N TROSY-HSQC of 2H/13C/15N 14-3-3ζ in the absence (blue) and presence 
of a 1:1 molar ratio of the Cby 18-mer (red). ......................................................................... 59	  
Figure 2.8 ITC thermograms for 14-3-3ζΔC12 ...................................................................... 60	  
 xiv 
 
Figure 2.9 Backbone resonance assignment of 14-3-3ζΔC12 ................................................ 61	  
Figure 2.10 NMR titration experiments of 14-3-3ζΔC12 with Cby peptides......................... 64	  
Figure 2.11 The mapping of chemical shifts on the crystal structure of the 14-3-3ζ/Cby 
complex................................................................................................................................... 65	  
Figure 2.12 Composite 1HN and 15N chemical shift perturbation analysis ............................. 66	  
Figure 2.13 Observed chemical shifts for 14-3-3ζΔC12 residues 204-215 ............................ 67	  
Figure 2.14 ITC thermograms for Cby 18-mer binding to all 14-3-3 isoforms...................... 70	  
Figure 2.15 ITC thermograms for Cby 18-mer binding to 14-3-3 phosphomimetics ............ 71	  
Figure 2.16 The 14-3-3ζ, Cby, β-catenin tripartite complex. ................................................. 76	  
Figure 3.1 Sequence of human Cby and peptides used in HDX-MS data analysis ................ 91	  
Figure 3.2 HDX kinetics of peptides in Cby........................................................................... 92	  
Figure 3.3 HDX-MS data of Figure 3.2 mapped onto a structural model of Cby for t=60 min
................................................................................................................................................. 93	  
Figure 3.4 Cby constructs used in this study .......................................................................... 96	  
Figure 3.5 CD spectra and thermal melts of Cby constructs .................................................. 97	  
Figure 3.6 NMR spectra of full-length Cby and CbyΔC20 .................................................... 98	  
Figure 3.7 NMR Spectra of C-Cby....................................................................................... 100	  
Figure 3.8 TC-1/Cby NMR titration experiments................................................................. 103	  
Figure 3.9 NMR titrations with TC-1/Cby constructs .......................................................... 104	  
Figure 3.10 TC-1/C-Cby NMR and ITC binding experiments............................................. 105	  
Figure 3.11 ITC thermograms for binding experiments between TC-1 and Cby constructs 106	  
 xv 
 
Figure 4.1 Schematic of Cby's coiled-coil, represented as helical wheels ........................... 118	  
Figure 4.2 CD spectra and thermal melts of full-length Cby coiled-coil mutants................ 125	  
Figure 4.3 1H-15N HSQC NMR spectra of full-length Cby-WT and coiled-coil mutants.... 127	  
Figure 4.4 NMR titrations with TC-1 and Cby coiled-coil mutants ..................................... 129	  
Figure 4.5 CD spectra and thermal melts of C-Cby coiled-coil mutants.............................. 132	  
Figure 4.6 1H-15N HSQC NMR spectra of C-Cby WT and C-Cby coiled-coil mutants ...... 133	  
Figure 4.7 Cby binding to β-catenin using pull-down assays and ITC ................................ 136	  
Figure 4.8 NMR titration experiment with C-Cby-2A and β-catenin .................................. 137	  
Figure 4.9 Characterization of β-catR10C............................................................................ 138	  
 
 
 
 
 
 
 
 
 
 
 
 xvi 
 
 
List of Abbreviations 
AANAT Serotonin-N-acetyltransferase 
Akt/PKB Protein Kinase B 
APC Adenomatous polyposis coli 
 β-TrCP F box/WD-repeat β-transducin repeat-containing protein 
C-Cby C-terminal Cby (residues 67-126) 
Cby Chibby 
CD Circular Dichroism 
CEP164 Centrosomal protein of 164 kDa 
CHOP C/EBP homologous protein 
CK1 Casein kinase Ia  
Coil-Cby Coiled-coil domain of Cby (residues 67-104) 
CRM-1 Chromosome Region Maintenance-1 
CtBP C-terminal binding protein 
DSS 2,2-dimethyl-2-sila-pentane-5-sulfonic acid  
DTT Dithiothreitol 
Dvl Dishevelled 
FAP Familial adenomatous polyposis 
FoxM1 Forkhead box M1 
Fz Frizzled 
GM130 Golgi matrix 130 
GSK3β Glycogen synthase kinase 3β  
HDAC Histone deacetylase 
HDX-MS Hydrogen-deuterium exchange mass spectrometry 
HSQC Heteronuclear Single Quantum Coherence 
ICAT Inhibitor of β-catenin and Tcf4 
IPTG Isopropyl-β-D-Thiogalactopyranoside 
ITC Isothermal titration calorimetry 
JNK2 c-Jun N-terminal kinase 2 
LRP 5/6 Low-density lipoprotein receptor-related protein 5/6 
 xvii 
 
MBP Maltose Binding Protein 
N-Cby N-terminal Cby (residues 1-63) 
NBPF1 Neuroblastoma breakpoint family member 1 
NES Nuclear export signal 
NLS Nuclear localization signal 
NMR Nuclear magnetic resonance 
NOESY Nuclear Overhauser effect spectroscopy 
Par-4 Prostate apoptosis response factor 4 
PCP Planar cell polarity pathway 
PDB Protein Data Bank 
TC-1 Thyroid cancer-1 
Tcf/Lef T cell factors/ lymphoid enhancer factor 
TEV Tobacco etch virus 
TROSY Transverse Relaxation Optimized Spectroscopy 
  
Ala (A) Alanine 
Arg (R) Arginine 
Asn (N) Asparagine 
Asp (D) Aspartic Acid 
Cys (C) Cysteine 
Gln (Q) Glutamine 
Glu (E) Glutamic Acid 
Gly (G) Glycine 
His (H) Histidine 
Ile (I) Isoleucine 
Leu (L) Leucine 
Lys (K) Lysine 
Met (M) Methionine 
Phe (F) Phenylalanine 
Pro (P) Proline 
Ser (S) Serine 
Thr (T) Threonine 
Trp (W) Tryptophan 
Tyr (Y) Tyrosine 
Val (V) Valine 
pS/pT phosphoserine / phosphothreonine 
1 
 
Chapter 1  
1 Introduction 
1.1 Introduction to Wnt Signaling 
Signaling pathways are critical systems utilized across animal life to coordinate 
cell-to-cell communication and regulate cellular functions.  A cell’s ability to recognize 
and respond to signaling molecules in the extracellular environment is crucial for 
development, tissue repair, immunity and homeostasis.  Strict regulation of these 
pathways is critical, as errors from signal transduction can lead to developmental defects 
or disease. 
The Wnt signaling proteins are involved in multiple developmental events in 
embryogenesis including body axis patterning and cell proliferation, and have been 
implicated in stem-cell control and adult cell homeostasis [1,2,3]. The Wnt proteins are 
part of a family of growth factors that are associated with three downstream pathways: 
the Wnt/β-catenin pathway, the Wnt/Ca2+ pathway (reviewed in [4]) and the planar cell 
polarity pathway (PCP) [5].  Each pathway has its own set of specific genes that are 
targeted upon stimulation [6,7].  Over the past three decades, the most heavily focused 
Wnt pathway in this field of study has been the β-catenin-dependent Wnt signaling 
pathway, also referred to as canonical Wnt signaling. Here, the transcriptional co-
activator β-catenin is a downstream component of the pathway, responsible for the 
activation of the pathway’s target genes [8].  
A simplified view of canonical Wnt signaling is illustrated in Figure 1.1 A.  In 
unstimulated conditions (-Wnt signal), cytoplasmic β-catenin exists as part of a large 
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protein complex, commonly referred to as the destruction complex, which contains the 
scaffolding proteins adenomatous polyposis coli (APC) and Axin [2,9].  β-catenin is 
phosphorylated on Ser/Thr residues on its N-terminus by serine/threonine kinases 
glycogen synthase kinase 3β (GSK3β) and casein kinase Iα (CK1) [10].  Phosphorylated 
β-catenin is subsequently recognized by the F box/WD-repeat β-transducin repeat-
containing protein (β-TrCP) and targeted for ubiquitin-dependent degradation by the 
proteasome [11].  Through this mechanism, cytoplasmic β-catenin levels are kept low, 
preventing this protein from entering the nucleus.  In the nucleus, the T-cell factor (Tcf) / 
Lymphoid enhancing factor (Lef) transcription factors, necessary for the expression of 
Wnt-specific target genes, interact with the transcriptional repressors Groucho, histone 
deacetylase (HDAC) and C-terminal binding protein (CtBP) [12,13].  
In the activated Wnt pathway, the Wnt proteins interact with the family of frizzled 
(Fz) receptors, which are members of the G-protein coupled receptor family, and the low-
density lipoprotein receptor-related protein 5/6 (LRP5/6) receptors [14].  The activated 
receptors lead to the stabilization and accumulation of β-catenin in the cytosol.  β-catenin 
that is free from the destruction complex is able to translocate to the nucleus where it 
binds to the Tcf/Lef transcription factors to activate Wnt signaling genes [15,16,17].  
A defined cellular mechanism by which β-catenin is stabilized has continually 
been developed and refined over the past two decades.  In a commonly presented model, 
the activated receptor complex promotes the recruitment of the cytoplasmic 
phosphoprotein Dishevelled (Dvl), a known interactor of Axin.  Dvl mediates the 
formation of LRP5/6 Wnt signalosomes through its multimerization [18], as well as 
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promotes the CK1 phosphorylation of the cytoplasmic domains of LRP5/6.  Dvl and the 
phosphorylated LRP5/6 collectively recruit Axin to the membrane [19].  The 
sequestration of Axin to the cell membrane effectively dissolves the destruction complex, 
leading to the stabilization of β-catenin.   
The collection of studies that have jointly developed models to describe β-
catenin’s stabilization have generally used over-expression strategies to study the 
destruction complex.  A recent study, conducted by Li et al. [20], which looked at the 
endogenous complex, proposed a different model. This study suggests that β-catenin is 
not released from the destruction complex upon Wnt signaling.  Instead, Wnt signaling 
suppresses β-catenin’s ubiquitination by promoting the dissociation of β-TrCP, causing 
the destruction complex to be saturated with phosphorylated β-catenin at the membrane.  
At this point, any newly synthesized, non-phosphorylated β-catenin is free to translocate 
to the nucleus and activate Wnt target genes. This new model is illustrated for 
comparison in Figure 1.1 B.  
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Figure 1.1 Wnt signaling models 
A.  A simplified model of the Wnt/β-catenin signaling pathway.  In the absence of a Wnt 
signal, the destruction complex is intact and β-catenin is targeted for ubiquitination by β-
TrCP, followed by degradation by the proteasome.  Upon activation, Axin is recruited to 
the membrane, leading to the dissolution of the destruction complex.  Stabilized β-catenin 
can then translocate to the nucleus and activate Wnt target genes.  B. A new Wnt/β-
catenin signaling model based on a study looking at endogenous destruction complex 
proteins [20].  Wnt activation recruits the intact destruction complex to the membrane 
and blocks the ubiquitination of β-catenin.  Any newly synthesized β-catenin proceeds to 
activate target genes.  Figure was adapted from figures generated by Clevers and Nusse 
[3].
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1.2 Wnt/β-catenin signaling in human disease and 
therapeutic development 
Mutations to proteins involved in Wnt signaling that lead to aberrant activation of 
the pathway are frequently observed in human cancers.  Germline mutations in the APC 
gene lead to a hereditary cancer syndrome called familial adenomatous polyposis (FAP) 
[21,22].  These patients carry heterozygous APC mutations, with the second allele 
frequently lost in individual cells during adulthood, leading to colon adenomas (polyps) 
[23].  Global-exome sequencing projects have shown that the majority of colorectal 
cancers carry inactivating APC mutations [24].  The loss of APC function causes 
stabilization of cytosolic β-catenin, where it can then constitutively interact with Tcf/Lef.  
In some rare cases of colorectal cancer where no APC mutations exist, Axin2 is mutated 
[25], or activating point mutations to the regulatory Ser/Thr residues of β-catenin’s N-
terminus are discovered [26].   
Mutations to Wnt pathway components are not limited to colorectal cancers.  For 
example, oncogenic β-catenin mutations have been observed in hepatocellular 
carcinomas, melanoma, Wilms tumour and liver, endometrial ovarian and prostate 
cancers (reviewed in [27]). Outside of cancer, the Wnt signaling pathway has been linked 
to type II diabetes, with the identification of specific single nucleotide polymorphisms 
(SNPs) to the Wnt proteins WNT5B [28], and WNT10B [29] as well as TCF7L2 [30].  
Moreover, aberrant Wnt signaling has been implicated in bone-density syndromes [31] as 
well as in Alzheimer’s disease [32].   
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With an expanding association to various human diseases, modulation or 
disruption of Wnt signaling through the discovery of small molecules has received 
extensive research efforts [33].  Presently, the frizzled and LRP receptors that bind to 
Wnt proteins have proven to be difficult to target pharmacologically as no effective 
small-molecule inhibitors currently exist.  However, the development of a biologic agent, 
a humanized antibody to the frizzled receptor named Vantictumab, has entered several 
clinical trials (https://clinicaltrials.gov/ct2/results?term=omp18R5&Search=Search).  
Small molecule screening for Wnt signaling modulators has yielded some success when 
targeting upstream components.  For instance, Axin stability is regulated by its poly-ADP 
ribosylation, a process catalyzed by the enzyme tankyrase [34].  Inhibition of tankyrase 
by molecules like IWR [35] and XAV939 [34] lead to elevated Axin levels which then 
destabilizes β-catenin.  Next, small-molecule inhibitors of the enzyme Porcupine 
represent one of the most specific Wnt signaling disruptors discovered to date [35].  
Porcupine mediates the attachment of palmitoleate, a 16-carbon monounsaturated fatty 
acid, to the Wnt proteins [36].  Wnt proteins that lack lipids are not secreted and as such, 
inactive Porcupine cannot produce active Wnt proteins.  A compound named IWP2 [35] 
has been shown to inactivate Porcupine with high selectivity and has been effectively 
used in cell culture experiments to knock down Wnt signaling [37]. 
 The most attractive drug target of canonical Wnt signaling is the Tcf/Lef and β-
catenin complex as it operates downstream of the pathway. However, disruption of the β-
catenin/Tcf or Lef complex may have undesired consequences; outside of Wnt signaling, 
β-catenin is a central component of adhesion junctions. Here, β-catenin links cadherins at 
the plasma membrane to α-catenin [38,39]. As Tcfs and Lefs share a common binding 
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site with E-cadherin [40], inhibitors that dislodge the β-catenin/Tcf or Lef complex may 
disrupt cell adhesions as well.  
Dislodging the β-catenin/Tcf or Lef complex by small molecules is a significant 
challenge, as the binding interface between these transcription factors and β-catenin 
extends over a large surface of β-catenin (Tcf, for example, buries over ~ 4800 Å of 
surface area [41]). While a few compounds have been suggested to disrupt complex 
formation, such as 2,4-diamino-quinazolines [42] or the molecules PKF115-854 and 
CGP049090 (screened by Lepourcelet et al. [43]), their specificity and efficacy have not 
been reported.  
1.3 Regulation of  β-catenin in Wnt signaling 
Multiple regulatory strategies employed by the cell focus on various stages of the 
Wnt pathway; from the cell membrane to the nucleus. Not surprisingly, β-catenin is a 
focal point. Many proteins are found to direct its subcellular localization or impede its 
transcription of target genes.  First, several regulatory mechanisms are in place to control 
the nuclear import and export of β-catenin. For instance, the forkhead box M1 (FoxM1) 
transcription factor, whose cellular levels are elevated by Wnt induction, efficiently 
promotes the nuclear localization of β-catenin (which it interacts directly with) through 
its functional nuclear localization signal (NLS) [44]. Another example comes from the 
work of Wu et al. [45], which demonstrated that the activation of Rac1/JNK2 is 
fundamental to the Wnt-mediated nuclear localization of β-catenin.  This study reveals 
that Wnt stimulation increases Rac1 activation, followed by JNK2 activation.  JNK2 then 
phosphorylates β-catenin on residues Ser191 and Ser605, which promotes β-catenin’s 
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nuclear localization. Last, in addition to playing roles in the destruction complex, both 
Axin and APC harbour a NLS and NES (nuclear export signal), enabling them to shuttle 
in and out of the nucleus along with bound β-catenin [46,47,48]. 
 Several proteins that antagonize the β-catenin/Tcf or Lef complex as a means of 
modulating Wnt signaling have been reported.  These proteins include inhibitor of β-
catenin and Tcf4 (ICAT) [49], the chromatin remodeling enzymes HDAC1 and HDAC2 
[50], the transcriptional repressor Kaiso [51] and the cell cycle regulator p15RS [52].  
Interestingly, the protein Chibby (Cby), first reported for its role in Wnt signaling by 
Takemaru et al. [53], represses β-catenin-mediated expression of Wnt target genes by the 
two mechanisms discussed above; it competes with the Tcf/Lef transcription factors for 
binding to β-catenin [53], and regulates β-catenin’s nuclear translocation in conjunction 
with the 14-3-3 proteins [54,55]. 
1.4 The Wnt signaling antagonist Chibby 
Cby is a 126-residue, 14.5 kDa protein that is evolutionarily conserved from human 
to fly (Figure 1.2).  Structurally, the protein’s N-terminal half (residues 1-63) is 
intrinsically disordered [56] while its C-terminal half (residues 64-126) harbors a coiled-
coil domain that promotes the protein’s dimerization [56,57].  The two structural halves 
of Cby work together to perform Cby’s function as an antagonist to the Wnt pathway.  
First, pulldown assays have demonstrated that Cby’s C-terminal half alone is sufficient 
for binding to β-catenin [53].  Meanwhile, Cby phosphorylation at residue serine 20 by 
the kinase Akt promotes Cby’s interaction with the scaffolding protein 14-3-3 [54]. This  
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Figure 1.2 Cby Multiple Sequence Alignment 
Multiple sequence alignment of Cby from human, mouse (Mus musculus), bovine 
(Bos Taurus), frog (Xenopus tropicalis), zebrafish (Danio rerio) and fly (Drosophila 
melanogaster).  Alignment was generated using T-Coffee [58] and figure was made using 
BoxShade.  Sequence features are labeled. 
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Cby/14-3-3 interaction promotes the nuclear exclusion of β-catenin and thus represses the 
transcriptional coactivator’s activity [54,55]. 
A study by Li et al. [55] demonstrated that Cby actively shuttles between the nucleus 
and cytoplasm via its NLS and NES.  Cby’s NLS is found at its very C-terminus 
(residues 123-126) and mediates binding with isoforms of the importin-α family, which 
are nuclear transport proteins. Cby’s NES is found within its N-terminal half (residues 
21-29) and interacts with nuclear export transporter chromosomal maintenance 1 
(CRM1).  Cby’s nuclear-cytoplasmic shuttling affects the subcellular distribution and 
signaling activity of β-catenin; immunofluorescence microscopy experiments [55] reveal 
that deletion of Cby’s NLS leads to cytoplasmic sequestration of β-catenin while loss-of-
function mutations to Cby’s NES lead to nuclear retention of β-catenin. TOPFLASH 
assays (a Tcf/Lef reporter kit used to measure Wnt signaling activity in cultured cells) 
were used to demonstrate that mutations to Cby’s NLS effectively repressed β-catenin 
signaling by trapping β-catenin in the cytoplasm.  Conversely, mutations to the NES 
caused Cby to have markedly reduced ability to antagonize β-catenin signaling, 
presumably due to their failure in translocating β-catenin to the cytoplasm. 
     The protein 14-3-3 stimulates the cytoplasmic sequestration of both Cby and β-
catenin through an unclear mechanism.  However, the study by Li et al. [55] provides 
some evidence that the 14-3-3/Cby interaction promotes Cby’s binding to CRM1 in the 
nucleus and inhibits Cby’s interaction with importin-α in the cytoplasm.  14-3-3 may 
accomplish repressed β-catenin mediated signaling if it promotes Cby’s export from the 
nucleus and prevents its import while Cby is in a β-catenin bound state.   
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Cby itself is regulated by a small protein named thyroid cancer 1 (TC-1) [59].  
TC-1 binds to Cby in competition with β-catenin, effectively abrogating Cby’s 
antagonism. Downstream gene analysis by Jung et al. [59] showed that TC-1 up-regulates 
β-catenin target genes such as LAMC2, MMP-7, MMP-14, c-Met, c-Myc and cyclin D1.  
Cby’s function in the Wnt pathway suggests that it may be a tumour suppressor 
gene.  However, very few studies have linked Cby to cancer.  Some studies have shown 
that Cby is downregulated in colon carcinoma [60] and pediatric ependymomas [61] cell 
lines.  Xu et al. [62] showed that Cby is highly downregulated in laryngeal squamous cell 
carcinoma (LSCC) tissues, however, no correlation between Cby expression and 
pathological features of LSCC were observed.   
An overview of Cby’s nucleo-cytoplasmic transport and its role in Wnt signaling 
is displayed in Figure 1.3 below.  Cby plays a crucial role in the Wnt/β-catenin pathway, 
yet the understanding of the structural mechanisms it utilizes to interact with its binding 
targets is still in need of investigation. The following sections will explore the known 
structural information on Cby and its Wnt signaling binding partners β-catenin, 14-3-3 
and TC-1. 
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Figure 1.3 Cby in Wnt Signaling 
Cby’s nucleo-cytoplasmic shuttling is mediated by the transport proteins importin-α and 
CRM1.  In Wnt signaling, Cby directly competes with the Tcf/Lef transcription factors 
for binding to β-catenin.  The protein TC-1 alleviates this antagonism.  Upon 
phosphorylation by Akt, Cby interacts with 14-3-3.  CRM1 then translocates Cby and 
bound β-catenin out of the nucleus. 
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1.5 Structural features and characterization of Cby 
Circular dichroism (CD) and NMR spectroscopies demonstrate that Cby’s N-terminal 
half (residues 1-64) is intrinsically disordered [56].  Disordered regions within proteins 
exist as an ensemble of structures, allowing them to form specific, but commonly low-
affinity interactions with their targets [63].  Their plasticity makes them well suited in 
signaling pathways, as the need for reversible binding and interaction with multiple 
partners is often necessary [64]. Cby’s N-terminus comprises the protein’s 14-3-3 and 
CRM1 binding motifs [54,55].   
Analysis of Cby’s sequence across species revealed the presence of a conserved 
coiled-coil motif along its C-terminal half [53].  Coiled-coils are common structural 
motifs, and typically consist of 2-5 α-helices wrapped around each other into a supercoil 
structure [65].  The simple structural design of coiled-coils makes them versatile folding 
motifs. They enable proteins to self-oligomerize, hetero-dimerize with compatible coiled-
coil domains on other proteins, or mediate interactions with proteins and DNA [66].  
Additionally, depending on their function, a coiled-coil may be highly thermostable, or 
may require volatility for dynamic folding or binding processes [66].  Coiled-coils are 
stabilized by the effective burial of hydrophobic side chains in the core of the supercoil.  
These motifs consist of a heptad repeat that follows a pattern of hydrophobic and 
charged/polar amino acids.  
A classic example of a coiled-coil motif is the basic-region leucine zipper [67]. 
They are found in many transcription factors, including c-fos and c-jun [68,69].  The 
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zipper mediates dimerization of these transcription factors, which is necessary for them to 
bind to their DNA binding elements.  Heptad repeats are commonly illustrated with 
helical wheel representations.  The seven positions of each repeat are commonly labeled 
a, b, c, d, e, f, g with positions a and d being hydrophobic residues and e and g 
predominantly charged/polar [70]. The leucine zippers are so named as leucines are 
predominantly found at position d of their heptad repeats.     
The first evidence of Cby’s self-association came from a yeast-two-hybrid 
experiment that used Cby as bait and ultimately pulled itself out [71].  Gel filtration and 
cross-linking experiments by Mofunanya et al. [57] demonstrated that Cby exists 
predominantly as a homodimer. The coiled-coil domain of human Cby is displayed in 
helical wheel format with four consecutive heptad repeats (residues 73-100) in Figure 
1.4.  Within the heptad repeats of the coiled-coil, there are four conserved leucines (L77, 
L84, L91 and L98) at position d in the helical wheel.  Additionally, the coiled-coil 
contains two conserved asparagines (N81 and N88), which are buried in the hydrophobic 
core (position a).  For dimeric coiled-coils, asparagine is commonly found at this position 
to promote parallel assembly of the coiled-coil.  The parallel assembly is the result of 
self-complementary hydrogen bonding of the two asparagines’ side-chains [72]. 
The dimerization of Cby has been shown to have functional significance in the 
Wnt signaling pathway.  Alanine mutations to the core leucine residues were previously 
shown to disrupt the coiled-coil and monomerize the protein [57].  While these 
monomeric mutants maintained the ability to bind to β-catenin and repress β-catenin 
mediated signaling, monomeric Cby was incapable of binding to importin-α, thus 
disrupting its nuclear import [57].  
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Figure 1.4 Cby's coiled-coil domain 
Helical wheel diagrams for the predicted Cby coiled-coil domain (residues 73-100).  Four 
heptad repeats, starting at position g (Glu 73), are displayed as parallel and homodimeric. 
Potential interfacial electrostatic bridges are drawn as broken blue lines. Model was 
generated using DrawCoil 1.0 (http://www.grigoryanlab.org/drawcoil/). 
 
 
 
 
 
16 
 
Biophysical studies of recombinantly expressed Cby are hindered by its 
insolubility [56].  Cby forms inclusion bodies upon expression in E. coli and must be 
purified using urea to denature the protein, followed by a refolding procedure.  Cby, with 
a predicted pI of 9.1, must be refolded in a low pH (pH 5) and low ionic strength buffer.  
This restrictive buffer requirement hinders the ability to conduct binding studies between 
Cby and its binding targets.  As the protein cannot be crystallized, due to its mostly 
disordered structure and insolubility, NMR spectroscopy is an attractive method for the 
structural characterization of this protein.  However, the coiled-coil domain of Cby 
suffers from severe line-broadening; only peaks corresponding to Cby’s N-terminus are 
observable in Cby’s 1H-15N HSQC spectrum.  Deuteration of the protein by expressing 
the protein in M9 salts with 100% D2O does not render these peaks observable.  The lack 
of observable resonances for residues within the coiled-coil domain may be the result of 
monomer-dimer exchange, tumbling time of the coiled-coil, or intramolecular 
conformational exchange [56].    
1.6 Structure of β-catenin and modes of interaction with 
Wnt signaling components 
Structurally, the 781-residue human β-catenin consists of a central scaffolding 
region (amino acids 141-664) made up of 12 armadillo repeats (R1-R12) which are 
flanked by intrinsically disordered N- and C-terminal domains (NTD and CTD) [73] 
(Figure 1.5 A). Between R12 and the CTD is a conserved helix, termed helix-C, 
comprised of residues 667-683 [74].  The armadillo repeats, named after the historical 
name for β-catenin in Drosophila [75], are comprised of ~ 42 residues which form three 
helices arranged in a triangular fashion [73].  The 12 armadillo repeats collectively form 
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an elongated superhelix that harbors a large, positively charged groove that functions as a 
binding site for many of β-catenin’s binding partners including Tcf [76], Lef [77], Axin 
[78], APC [79], E-cadherin [40] and ICAT [80]. Figure 1.5 B and C illustrate crystal 
structures of β-catenin in complex with these Wnt signaling partners.  Many of these β-
catenin interacting partners share overlapping binding regions and cannot bind β-catenin 
simultaneously [81,82].  As such, spatial segregation of these signaling components could 
be critical to their function, or competition may be necessary for the regulation of Wnt 
signaling.   
Tcf/Lef transcription factors all bind similarly to β-catenin [77], with their N-
terminal region binding in an extended state along armadillo repeats R5-R10 and a C-
terminal α-helix that interacts with repeats R2-R5.  Axin binds to the third and fourth 
armadillo repeats of β-catenin as a continuous helix [78]. APC contains multiple β-
catenin interaction motifs, which include three 15 amino acid (aa) repeats and seven 20-
aa repeats. Crystal structures revealed that the 15-aa and 20-aa repeats bound to R5-R8 of 
β-catenin.  Intriguingly, upon phosphorylation of the 20- aa repeats, a downstream region 
of APC adopts the ability to interact with R1-R5 of β-catenin, effectively enabling the 
phosphorylated protein to outcompete Axin for binding to β-catenin [83].  The antagonist 
ICAT is composed of an N-terminal 3-helix bundle and a disordered C-terminus.  The 3-
helix bundle is anchored within repeats R10-R12 of β-catenin while the disordered C-
terminus binds along repeats R5-R9, where it can displace Tcf/Lef [80].  
The majority of cellular β-catenin participates in adherens junctions, interacting 
with cadherins [84].  The cytoplasmic domain of E-cadherin interacts with armadillo  
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Figure 1.5 Structure of β-catenin and its binding partners 
A. Schematic of the major structural domains β-catenin. B.  Cartoon ribbon crystal 
structure of β-catenin (PDB: 3OUW, green) in complex with the structurally aligned 
proteins Lef-1 (3OUW, red), Tcf-4 (1JPW, blue), Axin (1QZ7, grey), APC (1JPP, cyan) 
and E-cadherin (1I7X, orange).  C. Structural alignment of Lef-1, Tcf-4, Axin and APC 
protein without the visual hindrance of β-catenin and the armadillo repeats they bind to. 
D. ICAT in complex with β-catenin (1LUJ). β-catenin from 1LUJ was superimposed 
onto a β-catenin molecule from a solved structure where helix C is observed (2Z6H). 
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repeats R5-R9.  Additionally, upon phosphorylation, a disordered region in E-cadherin 
interacts extensively with repeats R3-R4 [40].  A shared binding site between cadherins 
and Tcf/Lef makes targeting β-catenin therapeutically very challenging.  
Pull-down experiments using truncated β-catenin constructs revealed that the 
helix C is critical to the protein’s interaction with Cby, as Cby was observed to bind 
markedly weaker to a β-catenin construct comprising of only the armadillo repeat region 
[74]. However, detailed structural characterization of the Cby/β-catenin complex has 
been mired by the buffer incompatibility of the two proteins.  Additionally, NMR 
spectroscopy represents a challenging avenue to study this complex due to the severe line 
broadening experienced in Cby’s C-terminal half, as well as β-catenin’s large size (~ 88 
kDa) and elongated shape. 
1.7 Structure, function and binding modes of 14-3-3 
proteins 
Members of the 14-3-3 family are abundant, ~ 30 kDa acidic proteins found 
across all eukaryotic organisms [85].  These proteins were first discovered in 1967, and 
are named after the nomenclature used by the researchers Moore and Perez [86] in their 
systematic classification of proteins found in bovine brain tissue. Using DEAE-cellulose 
chromatography and starch-gel electrophoresis, the 14-3-3 proteins eluted in their 14th 
fraction of bovine homogenate and migrated to position 3.3 on their starch gels.  In 
mammals, there are seven heavily conserved isoforms of 14-3-3 (β, γ, ε, ζ, η, θ, σ) [87] 
(Figure 1.6 A).  These family members are able to form homo- or hetero-dimers, with 
differing levels of preference [88].  For example, the σ isoform preferentially forms 
homo-dimers [89] while ε prefers forming hetero-dimers [90]. 14-3-3 dimers interact 
20 
 
with hundreds of protein targets, including tumour suppressors, kinases, transcription 
factors, apoptotic factors and cytoskeletal proteins [91].  With so many binding partners, 
14-3-3 plays critical roles in cellular function such as signaling, cell cycle progression, 
intracellular trafficking, transcription and apoptosis [87].  Studies have demonstrated that 
14-3-3 is directly involved in cellular processes that drive tumour development [92] and 
form protein complexes found in neurodegenerative diseases including Creutzfeldt-Jacob 
disease (CJD), Parkinson’s and Huntington’s disease [93]. 
The crystal structures of all 14-3-3 isoforms have been solved and share an 
identical fold [88]. The 14-3-3 proteins are nearly entirely α-helical, consisting of nine α-
helices (numbered  αA-αI) tightly arranged to form a horseshoe like structure (Figure 1.6 
A).  A positively charged, concave groove comprised of helices αC, αE, αG and αI, 
serves as the binding interface for 14-3-3 ligands.  Since 14-3-3 proteins are dimeric, 
each monomer may scaffold two separate ligands.  These ligands may be the same 
protein or two distinct ligands.  Such a scenario could allow 14-3-3 to juxtapose two 
molecules against each other, allowing for molecular communication between the two 
ligands.  Alternatively, proteins with multiple 14-3-3 binding sites, such as PKCε, may 
bind to both 14-3-3 monomers simultaneously, increasing the affinity of the interaction 
through avidity [94].  Sequence analysis of 14-3-3 binding partners reveals two major 
binding motifs named mode I (RXX[pS/pT]XP) and mode II (RXXX[pS/pT]XP), where 
pS and pT represents phosphorylated serine and threonine respectively [95,96]. In crystal 
structures of solved 14-3-3 complexes, the phosphorylated serine residue is anchored in 
14-3-3’s binding groove by predominantly positively charged residues (in the human ζ 
isoform, they are K49, R56, R127 and Y128). Notably, not all 14-3-3 phosphorylated 
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binding targets conform to these modes [97] and some do not require phosphorylation at 
all [98].  
Bioinformatic analysis of 14-3-3 binding sites indicates that they are frequently 
found within disordered regions of proteins [99].  The plasticity of these disordered 
regions may facilitate the diffusive search for the 14-3-3 binding groove. While 14-3-3 
binding motifs make up the core contacts in 14-3-3 complexes, secondary contacts by 
residues out of the 14-3-3 motif may also interact with regions outside of the 14-3-3 
binding groove. For instance, the only full-length binding partner to have been 
successfully co-crystallized to 14-3-3, the 14-3-3/Serotonin N-acetyltransferase complex 
[100], displays such secondary contacts, while secondary contacts have also been 
demonstrated in 14-3-3 interactions with integrin tails [101].  As the 14-3-3 binding 
groove is heavily conserved amongst all isoforms, the presence of these secondary 
contacts may direct which isoforms bind to a particular target.  Such is the case with the 
phosphatase Cdc25, which binds to all 14-3-3 isoforms except the σ isoform [102].   
Cby’s 14-3-3 binding motif (RKSApSLS), located within its disordered N-
terminus, most closely resembles the mode II motif, with the main exception being a 
serine as opposed to a proline at the +2 position relative to the phosphoserine [54]. Co-
immunoprecipitation experiments revealed that Cby binds to at least three 14-3-3 
isoforms; ε, η and σ [54].  However, whether Cby can interact with the other isoforms of 
the 14-3-3 family, or if it preferentially binds particular isoforms is unknown.  While the 
importance of the Cby/14-3-3 interaction in Wnt signaling has been demonstrated, the 
structural details of the complex are not clear. 
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Figure 1.6 14-3-3 Sequence, Structure and its Canonical Binding Mode 
A. Sequence alignment of the seven human 14-3-3 isoforms generated using T-Coffee 
and illustrated using BoxShade. B. Cartoon representation of dimeric structure of 14-3-3 
(PDB: 1QJA) in complex with synthetic phosphorylated peptides. C. The phosphorylated 
serine residue of the synthetic peptide (pS) making polar contacts (black dotted lines) 
with 14-3-3 residues K49, R56, R127 and Y128. 
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1.8 The Cby antagonist TC-1 
The Cby antagonist and binding partner TC-1 was identified as a gene overexpressed 
in papillary thyroid cancer [103].  It enhances β-catenin signaling by relieving the 
suppression induced by Cby [59].   Its expression has been correlated with aggressive 
behavior in lung and gastric cancers, potentially through activation of the Wnt pathway 
[104,105].  
Structurally, the 106 residues of TC-1 contain no known functional domains.  CD and 
NMR spectroscopy experiments demonstrate that the protein is intrinsically disordered 
[106,107].  However, secondary structure propensity (SSP) scores, calculated using the 
Cα and Cβ chemical shifts, and backbone relaxation experiments reveal three regions 
(D44-R53, K58-A64, and D73-T88) in the C-terminal half of the protein with α-helical 
propensity [106] (Figure 1.7). 
Pull-down experiments by Jung et al. [59] showed that the C-terminal half of TC-1 
(residues 51-106) maintained the ability to interact with Cby while the N-terminal half 
(residues 1-60) could not.  This observation was confirmed by NMR binding 
experiments, in which TC-1’s Cby binding site was mapped to the three regions with α-
helical propensity [106]. 
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Figure 1.7 Previous TC-1 NMR Studies 
NMR spectroscopy reveals TC-1 is intrinsically disordered and contains three regions 
with α-helical propensity. A. 1H-15N HSQC of 15-N labeled TC-1. B. SSP scores for TC-
1 residues. Regions with α-helical propensity are labeled.  This figure has been adapted 
from figures generated in [106]. 
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1.9 Scope of thesis 
The partially disordered protein Cby is an antagonist of the Wnt/β-catenin pathway. 
Cby’s repression of β-catenin signaling is accomplished by two mechanisms: it competes 
with the Tcf/Lef transcription factors for binding to β-catenin, and facilitates β-catenin 
export from the nucleus. The Cby mediated nuclear export of β-catenin is dependent on 
Cby’s interaction with the adaptor protein 14-3-3. 14-3-3 can form a tripartite complex 
with Cby and β-catenin (Figure 1.8), and the formation of this complex is thought to 
enable β-catenin’s nuclear export.  The protein TC-1 abates Cby’s antagonism through 
competitive binding for Cby.  In this thesis, the structural details of Cby’s interactions 
with the Wnt signaling proteins 14-3-3, β-catenin and TC-1 were investigated. 
In Chapter 2, the 14-3-3/Cby complex was structurally characterized.  Using X-ray 
crystallography, the structure of the complex was solved.  A canonical binding mode 
between the two proteins was revealed.  NMR spectroscopy and isothermal titration 
calorimetry experiments reveal that residues flanking Cby’s 14-3-3 binding motif 
contribute to the interaction. 
 NMR studies on Cby have been hindered due to severe line broadening from 
residues within its C-terminal half.  To structurally analyze Cby’s coiled-coil domain, 
hydrogen-deuterium exchange mass spectrometry (HDX-MS) was used.  HDX-MS data 
revealed that Cby’s C-terminal ~25 residues are disordered, providing evidence for an 
additional structural element along with its disordered N-terminus and coiled-coil domain 
(Chapter 3).  Several Cby constructs that comprise various combinations of Cby’s 
structural elements were generated and their interactions with the protein TC-1 were 
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studied.  It was discovered that Cby’s C-terminal half alone (disordered N-terminus 
removed) binds to TC-1 as a dimer and with significantly greater affinity than the full-
length protein, demonstrating that Cby’s disordered regions regulate its target 
recognition. 
 A major challenge in structurally characterizing the Cby/β-catenin complex is 
buffer incompatibility.  Additionally, the severe line broadening experienced by Cby’s C-
terminal half, as well as the large elongated shape of β-catenin, represent significant 
obstacles for studying the complex using NMR spectroscopy.  In Chapter 4, alanine 
substitutions within the core of Cby’s coiled-coil proved effective in disrupting coiled-
coil formation and in the process increased the solubility of Cby and lead to the 
appearance of C-terminal peaks in HSQC spectra of mutant Cby proteins.  Importantly, 
the mutants retained the ability to interact with β-catenin in an NMR titration experiment, 
suggesting Cby may bind to β-catenin as a monomer.  Conversely, these mutants failed to 
interact with TC-1, providing additional evidence that Cby binds to TC-1 as a dimer. 
Using a variety of biophysical techniques, the work presented in this thesis 
provides valuable structural insights into how Cby employs its disordered regions and 
coiled-coil domain to interact with Wnt signaling binding partners. 
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Figure 1.8 The Cby/14-3-3/β-catenin Tripartite Complex 
Schematic of Cby binding to 14‐3‐3 (PDB: 1QJA) and β-catenin (PDB:2Z6H).Cby 
utilizes its C‐terminus to bind to the helix C of β‐catenin and its phosphorylated (S20) 
N‐terminus binds to 14‐3‐3. 
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Chapter 2  
2 Structural Analysis of the 14-3-3ζ/Chibby Interaction 
Involved in Wnt/β-catenin Signaling 
2.1 Introduction 
Chibby (Cby) is a small (14.5 kDa), highly conserved protein that functions as a 
Wnt/β-catenin signaling antagonist [1].  While the Wnt pathway plays crucial roles in cell 
proliferation and differentiation, embryonic development and tissue homeostasis, its 
dysregulation contributes to the pathogenesis of an array of human disorders, including 
cancer [2,3].  Because of this, pharmacological modulation of the pathway has great 
therapeutic potential for disease treatments [4,5,6,7]. 
 Activation of the Wnt pathway promotes the stabilization of the transcriptional 
co-activator β-catenin within the cytoplasm, allowing it to translocate to the nucleus and 
bind to Tcf/Lef (T cell factor/lymphoid enhancer factor) transcription factors to activate 
Wnt target genes [8,9,10,11].  Multiple regulatory strategies employed by the cell focus 
on various stages of the Wnt pathway [12], with β-catenin being a focal point.  Cby is 
one such regulatory protein, suppressing β-catenin-mediated signaling via two distinct 
molecular mechanisms.  First, in the nucleus, it competes with the Tcf/Lef transcription 
factors for binding to β-catenin [1].  Secondly, Cby facilitates β-catenin export from the 
nucleus in conjunction with the proteins 14-3-3 and the nuclear export receptor 
chromosomal region maintenance 1 (CRM1) [13,14].  In this mode of regulation, Cby 
forms a stable trimolecular complex with 14-3-3 and β-catenin [13].  Interestingly, 
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binding of 14-3-3 to Cby also leads to an enhanced interaction between Cby and CRM1, 
promoting nuclear exclusion of Cby-bound β-catenin [14].   
The ability of the 126-residue human Cby to function as a scaffold protein likely 
arises from its partially disordered nature.  It is well documented that intrinsically 
disordered proteins bind to multiple targets by adopting different conformations or via 
linear motifs located at different regions in the proteins [15,16,17].  Previous work has 
shown that Cby consists of an unstructured N-terminus and contains a coiled-coil motif 
within its C-terminus (residues 73-100) that enables dimerization [18,19].  Cby uses its 
C-terminus to bind to β-catenin [1], although residues critical for this interaction have yet 
to be elucidated.  14-3-3 recognizes the motif 16RKSA(pS)LS22 located in the disordered 
N-terminus of Cby, when the serine 20 residue is phosphorylated by the kinase Akt [13].  
In this manner, N- and C-terminal binding modules on Cby work together to facilitate the 
nuclear export of β-catenin; however, how Cby forms such complexes from a structural 
standpoint remains unknown.  Our work here focuses on elucidating the binding mode 
between Cby and 14-3-3.    
The 14-3-3 proteins, which consist of seven isoforms in mammals (β, ɛ, η, γ,  θ, ζ 
and σ), function as adaptor molecules and are involved in a large range of cellular 
processes, including apoptosis, DNA damage response and transcriptional regulation 
[20].  Structurally, the ~30 kDa 14-3-3 proteins assemble into homo- or heterodimers, 
with each monomer composed of nine anti-parallel alpha-helices (αA-αI) [21].  An 
amphipathic groove composed of helices αC, αE, αG, and αI comprise the ligand-
binding interface.  Generally, 14-3-3 isoforms recognize three consensus binding motifs: 
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RXX(pS/pT)XP (mode I), RXXX(pS/pT)XP (mode II) and (pS/pT)X1-­‐2-­‐COOH (mode 
III) where pS/pT represents phosphorylated serine/threonine [22,23].  However, there are 
several 14-3-3 binding partners that deviate significantly from these canonical motifs, 
including examples of non-phosphorylated partners [24,25].  
With hundreds of binding partners discovered to date [26], the 14-3-3 proteins are 
classified as signaling hub proteins.  Interestingly, many well-structured hub proteins are 
found to preferentially bind to unstructured proteins [15].  In fact, the vast majority of 14-
3-3 binding motifs are either found or predicted to be within disordered regions [27,28].  
While this is due in large part to the phospho-dependence of 14-3-3 interactions, as 
kinases predominantly target unstructured regions for phosphorylation [29], the structural 
plasticity of 14-3-3 binding motifs and their neighbouring residues allows 14-3-3 proteins 
to target many different proteins with high specificity. 
14-3-3 targets are hypothesized to bind to 14-3-3 via primary and secondary 
interactions (discussed by Yang et al. [21]).  The primary interactions are made between 
the 14-3-3 binding motif (including the pS/pT residue) of the target and a conserved 
binding groove in the 14-3-3 protein.  Secondary interactions occur when residues 
flanking the target’s 14-3-3 binding-motif contact regions outside of the conserved 14-3-
3 binding groove.  While various crystal structures of 14-3-3 complexes have been 
solved, the majority of them have been co-crystallized with short peptides.  Observable 
electron density is typically only present for 4-10 residues flanking the phosphorylated 
residue of the target peptide.  While this provides a structural basis for the primary 
contacts of the interaction, information regarding the secondary contacts is limited.  To 
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date, only one (nearly) full-length, globular partner has been co-crystallized with 14-3-3 
[30].  
The disordered Cby is able to interact with at least three of the seven 14-3-3 
isoforms (ɛ, η and ζ) [13], however, whether it can bind to the β, θ, γ, or η isoforms is 
unknown.  Its 14-3-3 binding motif (16RKSA(pS)LS22) closely resembles the mode II 
motif (RXXX(pS/pT)XP), the difference being that Cby contains a serine instead of 
proline at the +2 position from the phosphoserine.  It is noteworthy that even though 
proline is found to be the +2 residue in ~ 50% of known 14-3-3 binding motifs, serine is 
in fact the second most commonly found amino acid at that position [25].  To our 
knowledge, no 14-3-3/phosphopeptide structure with serine as the +2 residue has been 
determined to date. 
In this work, the crystal structure of 14-3-3ζ in complex with an 18-residue 
phosphorylated Cby-derived peptide was solved to reveal the primary binding 
interactions.  Secondary interactions between 14-3-3 and the Cby peptide were further 
investigated by using nuclear magnetic resonance (NMR) spectroscopy and isothermal 
titration calorimetry (ITC).  By combining the X-ray and NMR techniques, we were able 
to obtain additional molecular details of the binding interface of Cby on 14-3-3.  
Additionally, Cby was shown to interact with all seven human isoforms of 14-3-3. 
Notably, the backbone assignment of 14-3-3ζ completed in this work will also facilitate 
mapping of regions on the 14-3-3ζ surface that are involved in binding other targets.    
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2.2 Materials and Methods 
2.2.1 Expression and Purification of 14-3-3ζ 
The human 14-3-3ζ and 14-3-3σ ORFs were purchased from GeneCopoeia and 
were each transferred into a Gateway® pDEST17 vector (Invitrogen).  The 14-3-3ζ∆C12, 
where the 12 C-terminal residues were deleted, was then generated from the full-length 
construct using the QuikChange II Site-Directed Mutagenesis Kit (Strategene).  The 
constructs for human 14-3-3 β, ε, γ, η, and θ were kindly gifted by the Structural 
Genomics Consortium. All 14-3-3 proteins used in this work had their DNA constructs 
sequenced.  14-3-3 proteins were expressed as His-tagged protein in Escherichia coli (E. 
coli) BL21 (DE3) (14-3-3 β, ε, γ, η, and θ) or E. coli BL21 pLysS (14-3-3ζ, 14-3-3ζ∆C12 
and 14-3-3σ) in M9 medium. For unlabeled protein, protein expression was induced at an 
O.D.600 of 0.9 by adding 0.75 mM IPTG at 18 ºC for 24 h. The 15N, 13C, 2H labeled 14-3-
3ζ∆C12 was produced by growing E. coli in deuterated M9 medium.  Cells adapted to 
70% D2O were used to inoculate a 1 L culture of M9 prepared in 100% D2O.  Cells were 
grown at 37 °C and overexpression was induced at an O.D.600 of 0.6 with 0.75 mM IPTG.  
After a 60-h induction at 18 °C, the cells were harvested.  All 14-3-3 constructs used in 
this study were purified from the crude lysate by affinity chromatography using Ni 
Sepharose™ Fast Flow beads (Amersham Biosciences).  The tag was then cleaved by 
overnight incubation with His-tagged tobacco etch virus (TEV) protease at 25ºC.  The 
cleaved 14-3-3 was purified from TEV by passing the mixture through Ni Sepharose™ 
Fast Flow beads.  The final yields for the 14-3-3ζ proteins were ~50 mg per L of M9 
media (including deuterated media). All 14-3-3 proteins were analyzed on SDS-PAGE 
for purity and analyzed for correct mass using electrospray ionization mass spectrometry. 
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2.2.2 Peptide Synthesis 
The Cby peptides used in this study were purchased from GenScript USA Inc. and 
the Tufts University Core Facility.  From GenScript USA Inc.: Cby 13-mer (NH2-
12KTPPRKSASLSNL24-COOH), Cby S20D 13-mer (NH2-12KTPPRKSADLSNL24-
COOH), Cby S20E 13-mer (NH2-12KTPPRKSAELSNL24-COOH), pCby 13-mer (NH2-
12KTPPRKSApSLSNL24-COOH) and pCby 18-mer (NH2-
12KTPPRKSApSLSNLHSLDR29-COOH).  From Tufts: pCby 7-mer (Ac-
16RKSApSLS22-NH2), pCby 11-mer (NH2-12KTPPRKSApSLS22-NH2), pCby S22P 7-mer 
(Ac-16RKSApSLP22-NH2), pCby S22P 13-mer (NH2-12KTPPRKSApSLPNL24-COOH) 
and pCby S22P 18-mer (NH2-12KTPPRKSApSLSNLHSLDR29-COOH).  Peptides were 
dissolved and dialyzed in 50 mM sodium phosphate, 100 mM NaCl at pH 6.8 for ITC and 
NMR experiments. 
2.2.3 Crystallization and Structure Determination 
 Crystals grew within 2 months at 4ºC in sitting drops containing 1 µL of complexed 
14-3-3ζ (10 mg/mL) and phosphorylated Cby 18-mer peptide (protein:peptide molar ratio 
1:4) in 20 mM Tris, pH 7.5, and 100 mM NaCl and 1 µL of reservoir solution containing 
200 mM NH4HCO2 and 16-20% PEG 3350.  The mother liquor with 15% glycerol served 
as the cryoprotectant for flash-cooling in liquid nitrogen.  Data were collected at the 
Macromolecular Crystallographic Facility (University of Western Ontario).  The structure 
was solved via rigid body molecular replacement, using Protein Data Bank entry 1QJA 
(14-3-3ζ in complex with mode II peptide) [31] as the starting model.  The Cby peptide 
was built manually using Coot [32] and refinement was carried out using PHENIX [33]. 
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2.2.4 NMR Experiments 
All NMR experiments were performed using 15N, 13C, 2H-labeled protein samples 
in 50 mM sodium phosphate, 100 mM NaCl at pH 6.8.  Samples contained 10% D2O and 
1 mM 2,2-dimethyl-2-sila-pentane-5-sulfonic acid (DSS) as 1H chemical shift reference.  
NMR experiments for the backbone resonance assignment of 14-3-3ζ∆C12 were 
conducted at 25 °C on a Bruker Avance 800 MHz (National University of Singapore) 
spectrometer equipped with cryogenic probe.  Sequential assignments were obtained 
from 1H-15N TROSY HSQC, HNCACB, HN(CO)CACB and 15N-NOESY-HSQC 
spectra.  Data were processed using NMRPipe [34] and analyzed using CARA [35].  
For the NMR titrations, either phosphorylated Cby 7-mer or 18-mer peptides were 
titrated into 600 µL of ~ 200 µM 15N, 13C, 2H labeled 14-3-3ζ∆C12 until a 3:1 (peptide: 
14-3-3ζ∆C12) molar ratio was reached.  A 1H-15N HSQC spectrum was collected for 
each titration point for a total of 12 points for the pCby WT 7-mer and 18-mer and 6 
points for the pCby S22P 18-mer.  All spectra were analyzed using NMRView [36].   
2.2.5 Isothermal Titration Calorimetry (ITC) Experiments 
ITC experiments were performed on a VP-ITC instrument (MicroCal) at 25 °C.  
The protein and peptide samples were dialyzed into a buffer containing 50 mM sodium 
phosphate, 100 mM NaCl, 1 mM DTT at pH 6.8 and degassed before the experiments.  
For ITC experiments testing the binding of the Cby 18-mer to all 14-3-3 isoforms, as well 
as the 14-3-3ζ S184E and 14-3-3σ S186E mutants, the buffer used comprised 20 mM 
MES, 100 mM NaCl, pH 6.5.  In a typical experiment, 5 µL aliquots of  ~1-2 mM peptide 
were titrated stepwise into the 1.4 mL sample cell containing ~100-200 µM 14-3-3.  The 
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association constant (Ka), molar binding stoichiometry (n) and the binding enthalpy (∆H), 
entropy (∆S) and Gibbs free energy (∆G) were determined by fitting the binding isotherm 
to a one-site model with MicroCal Origin7 software.  All ITC experiments were 
performed in duplicate. Peptide and protein concentrations were determined from amino 
acid analysis (Amino Acid Analysis Facility, SickKids, Toronto, ON). 
2.2.6 Accession Numbers 
The atomic coordinates for the 14-3-3ζ/Cby complex have been deposited in the 
Protein Data Bank under accession number 4WRQ.  The 1H, 15N and 13Cα/β chemical 
shifts of the backbone resonances have been deposited in the BioMagResBank 
(http://www.bmrb.wisc.edu), under BMRB accession number 25231. 
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2.3 Results 
2.3.1 Phosphorylation of serine 20 on Cby is critical for its binding 
to 14-3-3ζ 
A previous study by Li et al. [13] showed that S20 of Cby is essential for its 
interaction with 14-3-3, with the binding being regulated by the phosphorylation of this 
serine residue.  To quantitatively assess the importance of the phosphorylation of S20 to 
the complex formation with 14-3-3ζ, we have used ITC to measure the affinities of a Cby 
peptide (12KTPPRKSASLSNL24) encompassing the 14-3-3 binding motif, in both its non-
phosphorylated and phosphorylated forms, to 14-3-3ζ.  The same peptides containing the 
phospho-mimetic mutants S20D and S20E were also included in this study.  Our data 
show that only the phosphorylated Cby peptide was able to interact with 14-3-3ζ (KD ~ 
15 µM, Table 2.1 and 2.2), while the other three peptides display no observable binding 
(Figure 2.1).  Importantly, the phospho-mimetic mutations were unable to rescue the 
binding, indicating that the Cby/14-3-3ζ association is driven by the phosphate group on 
S20. 
 
Figure 2.1 ITC thermograms with unphosphorylated Cby peptides 
ITC thermograms for titrations of unphosphorylated or phospho-mimetic Cby peptides to 
14-3-3ζ. A. Cby WT 13-mer.  B. Cby S20D 13-mer.  C. Cby S20E 13-mer. 
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2.3.2 Flanking residues of the consensus 14-3-3 binding motif play 
important roles in the Cby/14-3-3ζ association 
Next, we assessed the contributions of residues flanking the consensus 14-3-3 
binding motif of Cby to the interaction with 14-3-3ζ.  The results of our ITC 
measurements show that a 7-mer Cby peptide (16RKSA(pS)LS22) comprising the minimal 
14-3-3 binding motif bound to 14-3-3ζ with a KD of ~44 µM (Table 2.1 and 2.2, Figure 
2.2).  Interestingly, phosphopeptides of increasing length exhibit a systematic increase in 
binding affinity to 14-3-3ζ (the results are summarized in Tables 2.1 and 2.2 and the 
thermograms are shown in Figure 2.2).  First, a Cby 11-mer peptide which contains 4 
additional residues (12KTPP15) than the Cby 7-mer peptide (16RKSA(pS)LS22) bound with 
more than two-fold greater affinity than the Cby 7-mer, with a KD of ~18 µM.  A Cby 13-
mer, with a 2 residue C-terminal extension to the 11-mer (23NL24), bound with only 
slightly higher affinity, with a KD of ~15 µM.  Lastly, an 18-mer, which contains a five-
residue C-terminal extension to the 13-mer (25HSLDR29), bound with nine-fold greater 
affinity compared to the 7-mer, with a KD of ~5 µM.  The results clearly indicate that 
residues flanking the binding-motif on Cby play significant roles in mediating the 
interaction with 14-3-3ζ. 
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Table 2.1 Thermodynamic parameters of binding of phosphorylated Cby peptides to 
14-3-3 
Thermodynamic parameters for the binding of phosphorylated Cby peptides to 14-3-3. A 
duplicate set of experimental values for all ITC experiments is reported in Table 2.2. 
a Binding stoichiometry of monomeric 14-3-3 and Cby peptide. 
bKd is the dissociation constant ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs 
free energy upon binding at T=298.15 K, respectively. 
 
 
 
 
 
Peptide na Kdb 
(10-6 M) 
∆Hb 
(kcal/mol) 
T∆Sb 
(kcal/mol) 
∆Gb 
(kcal/mol) 
In ITC Cell: 14-3-3 ζ      
WT Cby      
Cby 7-mer 
16RKSA(pS)LS22 
1.01 43.5 ± 1.9 -3.35 ± 0.06 2.60 -5.95 ± 0.03 
Cby 11-mer 
12KTPPRKSA(pS)LS22 
0.95 17.5 ± 0.6 -3.26 ± 0.02 3.23 -6.49 ± 0.02 
Cby 13-mer 
12KTPPRKSA(pS)LSNL24 
1.00  14.5 ± 0.6 -2.63 ± 0.02 3.97 -6.60 ± 0.02 
Cby 18-mer 
12KTPPRKSA(pS)LSNLHSLDR29 
0.96 4.6 ± 0.2 -4.35 ± 0.05 2.93 -7.28 ± 0.03 
      
Cby Mutants      
Cby 7-mer S22P 
16RKSA(pS)LP22 
1.03 2.9 ± 0.05 -6.16 ± 0.01 1.39 -7.55 ± 0.01 
Cby 13-mer S22P 
12KTPPRKSA(pS)LPNL24 
1.06 1.1 ± 0.03 -4.64 ± 0.01 3.49 -8.13 ± 0.02 
Cby 18-mer S22P 
12KTPPRKSA(pS)LPNLHSLDR29 
1.05 0.36 ± 0.01 -8.03 ± 0.02 0.76 -8.79 ± 0.02 
Cby 18-mer L24A 
12KTPPRKSA(pS)LSNAHSLDR29 
0.99 21.3 ± 1.7 -1.56 ± 0.05 4.81 -6.37 ± 0.05 
      
In ITC Cell: 14-3-3 ζ K49A      
Cby 18-mer WT 
12KTPPRKSA(pS)LSNLHSLDR29 
1.01 3.8 ± 0.3 -4.16 ± 0.05 3.23 -7.39 ± 0.05 
Cby 18-mer S22P 
12KTPPRKSA(pS)LPNLHSLDR29 
1.07 1.9 ± 0.2 -7.13 ± 0.03 0.67 -7.80 ± 0.06 
      
In ITC Cell: 14-3-3 ζ ΔC12      
Cby 13-mer 
12KTPPRKSA(pS)LSNL24 
0.99 14.9 ± 0.9 -2.08 ± 0.03 4.50 -6.58 ± 0.04 
Cby 18-mer 
12KTPPRKSA(pS)LSNLHSLDR29 
1.04 6.8 ± 0.4 -3.35 ± 0.06 3.70 -7.05 ± 0.03 
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Table 2.2 Duplicate set of thermodynamic parameters for the binding of 
phosphorylated Cby peptides to 14-3-3ζ 
Peptide na Kdb 
(10-6 M) 
∆Hb 
(kcal/mol) 
T∆Sb 
(kcal/mol) 
∆Gb 
(kcal/mol) 
In ITC Cell: 14-3-3 ζ      
WT Cby      
Cby 7-mer 
16RKSA(pS)LS22 
0.94 47.6 ± 1.6 -3.70 ± 0.04 2.20 -5.90 ± 0.02 
Cby 11-mer 
12KTPPRKSA(pS)LS22 
0.96 17.5 ± 0.6 -3.27 ± 0.02 3.22 -6.49 ± 0.02 
Cby 13-mer 
12KTPPRKSA(pS)LSNL24 
1.07  12.8 ± 0.5 -2.60 ± 0.03 4.07 -6.67 ± 0.02 
Cby 18-mer 
12KTPPRKSA(pS)LSNLHSLDR29 
0.94 4.9 ± 0.3 -4.33 ± 0.06 2.91 -7.24 ± 0.04 
      
Cby Mutants      
Cby 7-mer S22P 
16RKSA(pS)LP22 
1.02 3.2 ± 0.1 -6.21 ± 0.02 1.29 -7.50 ± 0.02 
Cby 13-mer S22P 
12KTPPRKSA(pS)LPNL24 
1.02 1.3 ± 0.04 -4.70 ± 0.01 3.33 -8.03 ± 0.02 
Cby 18-mer S22P 
12KTPPRKSA(pS)LPHSLDR29 
1.08 0.38 ± 0.01 -7.97 ± 0.01 0.79 -8.76 ± 0.02 
Cby 18-mer L24A 
12KTPPRKSA(pS)LSNAHSLDR29 
1.05 25.0 ± 2.5 -1.37 ± 0.05 4.91 -6.28 ± 0.06 
      
In ITC Cell: 14-3-3 ζ K49A      
Cby 18-mer WT 
12KTPPRKSA(pS)LSNLHSLDR29 
1.07 5.5 ± 0.6 -3.76 ± 0.07 3.41 -7.17 ± 0.06 
Cby 18-mer S22P 
12KTPPRKSA(pS)LPHSLDR29 
0.97 1.8 ± 0.1 -6.67 ± 0.04 1.17 -7.84 ± 0.03 
      
In ITC Cell: 14-3-3 ζ ΔC12      
Cby 13-mer 
12KTPPRKSA(pS)LSNL24 
1.06 14.5 ± 0.6 -2.08 ± 0.03 4.52 -6.60 ± 0.02 
Cby 18-mer 
12KTPPRKSA(pS)LSNLHSLDR29 
1.02 8.5 ± 0.5 -3.15 ± 0.04 3.77 -6.92 ± 0.03 
a Binding stoichiometry of monomeric 14-3-3 and Cby peptide. 
bKd is the dissociation constant. ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs 
free energy upon binding at T=298.15 K, respectively. 
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Figure 2.2 ITC thermograms for various phosphorylated WT and mutant Cby 
peptides titrated into 14-3-3ζ 
A. Cby 7-mer. B. Cby 11-mer. C. Cby 13-mer. D. Cby 18-mer. E. Cby S22P 7-mer F. 
Cby S22P 13-mer. G. Cby S22P 18-mer. H. Cby L24A 18-mer. 
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2.3.3 Molecular basis of the interaction between 14-3-3ζ and the 
non-canonical mode II binding-motif of Cby 
 We used X-ray crystallography to elucidate the molecular basis of the 14-3-3ζ/Cby 
interaction.  Purified 14-3-3ζ protein was co-crystallized with the phosphorylated Cby 
18-mer (12KTPPRKSA(pS)LSNLHSLDR29) and diffraction data were collected to a 
resolution of 2.41 Å (Table 2.3).  The 14-3-3ζ protein, which crystallized as the typical 
cup-shaped dimer [20], has the Cby peptide bound in an extended conformation to each 
14-3-3 monomer (Figure 2.3 A).  The dimer comprises the asymmetric unit of the crystal, 
and the visible electron density was slightly more extensive for the peptide bound to the 
B-chain of the dimer. Thus, of the 18 residues in the Cby peptide, eight residues, 
18SA(pS)LSNLH25, were resolved in the peptide bound to the 14-3-3 B-chain (Figure 2.3 
B) and seven residues, 18SA(pS)LSNL24, for that bound to the 14-3-3 A-chain (not 
shown).  Both bound peptides adopted similar conformations and made the same 
interactions with the 14-3-3 protein.  The lack of observable electron density for the 
remaining residues suggests that they remain flexible within the complex.  
 The overall structural features of the 14-3-3ζ/Cby complex are similar to that of 
other 14-3-3ζ/phosphopeptide complexes.  The Cby peptide occupies the conserved 
binding groove of 14-3-3 with the same orientation as other phosphopeptides previously 
characterized.  The hydrogen bonding potential of the phosphate group on pS20 is fully 
realized, with two hydrogen bonds made to each of R56 and R127, and another hydrogen 
bond to the side-chain hydroxyl of Y128 (Figure 2.3 C); 3 water molecules and the side 
chain of Cby-S22 mediate four additional hydrogen bonds to the phosphate oxygens.  
Thus, each of the phosphate oxygens has 3 hydrogen bonding partners positioned in an  
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Table 2.3 Crystallographic data collection and refinement statistics 
Values in parentheses refer to the highest resolution shell. 
Data Collection  
Wavelength (Å) 1.54179 
Cell Parameters   
a, b, c (Å) 70.83, 71.96, 130.99 
Space group P212121 
Resolution (Å) 65.49 – 2.41 (2.53-2.41) 
Total reflections 139,670 (16,075)  
Unique reflections 26,474 (3445) 
Rmerge 0.072 (0.516) 
Completeness (%) 98.4 (89.5) 
Multiplicity 5.3 (4.7) 
I/σ(I) 13.9 (3.2) 
  
Refinement  
Rwork/Rfree (%) 0.203/0.256 
RMSD from ideal values  
Bonds (Å) 0.008 
Angles  (°) 1.12 
Overall mean B values (Å2)  
Protein 21.71 
Peptide 26.69 
Solvent 19.22 
Number of amino acid residues per 
asymmetric unit 
464 
Number of water molecules 147 
Ramachandran plot  
Favoured regions (%) 98 
Allowed regions (%) 1.8 
Disallowed regions (%) 0.2 
Cβ deviations greater than 0.25 Å 0 
 
 
 
 
51 
 
 
 
Figure 2.3 Crystal structure of the 14-3-3ζ/Cby 18-mer complex 
A. Crystal structure of the 14-3-3ζ /Cby 18-mer complex.  Each 14-3-3ζ monomer 
(coloured orange and blue) is bound to one Cby phosphopeptide.  B. Final 2Fo − Fc 
electron density of 14-3-3ζ (blue mesh) and Cby 18-mer (green mesh) contoured to 1σ.  
C. Polar contacts (black hashed lines) between 14-3-3ζ residues (light blue sticks) and the 
Cby 18-mer (green sticks). 
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ideal tetrahedral arrangement, explaining why mutation of S20 to D or E fails to promote 
high affinity binding of Cby to 14-3-3ζ.  The peptide is further coordinated by hydrogen 
bonds between the carboxamide of 14-3-3ζ-N224 with the backbone nitrogen and 
carbonyl of Cby-A19, the carboxamide of 14-3-3ζ-N173 to the backbone nitrogen of 
Cby-L21, and the side-chain of either E180 (chain-C) or W228 (chain-D) of 14-3-3ζ to 
the hydroxyl group on the side-chain of Cby-S18.  Intra-chain contacts exist within the 
Cby peptide as well.  On chain-D of the model, consisting of residues 18SA(pS)LSNLH25, 
the pS20 amide is hydrogen bonded to the N23 side-chain, the phosphate group itself on 
S20 hydrogen bonds with the hydroxyl group on the S22 side-chain, the pS20 carboxyl 
contacts both the amide and the side-chain of N23 and the carboxyl of L21 contacts the 
amide of L24. 
2.3.4 An S22P mutation to Cby enhances its interaction to 14-3-3ζ 
 As mentioned, Cby comprises a serine (S22) in the +2 position to the 
phosphoserine, as opposed to the canonical proline.  A comparison between the 14-3-
3ζ/Cby structure with other 14-3-3ζ/phosphopeptide complexes with different +2 residues 
[including the canonical proline (Raf1), aspartate (PKCε [37]), glycine (Histone H3 [38]), 
threonine (β2 integrin [39]) and leucine (α4 integrin [40])], reveals that the S22 side 
chain is oriented uniquely, projecting between 14-3-3ζ residues R56 and K49 (Figure 
2.4).  Also, superimposition of these peptides onto Cby demonstrates that the backbones 
of residues -2 to +1 typically align well but diverge quickly C-terminally from the +2 
residue. 
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Figure 2.4 Structural comparison of 14-3-3ζ-bound Cby with other 14-3-3 binding 
motifs comprising various +2 residues 
Residues K49 and R56 are coloured yellow on the white surface representation of 14-3-
3ζ. Structural and sequence alignment of Cby (green sticks) with the binding-motifs of A. 
Raf1 (pink sticks, PDB: 3CU8), B. PKCε (orange sticks, PDB: 2WH0), C. Histone H3 
(white sticks, PDB: 2C1N), D. β2 integrin (blue sticks, PDB: 2V7D) and E. α4 integrin 
(purple sticks. PDB: 4HKC).  The Cα RMSD values were computed by subtracting a Cα 
distance matrix between the -2 and +1 residues of Cby and each peptide as well as the -2 
and most C-terminal residue in the respective alignments. 
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With the side chain on Cby-S22 distinctively positioned relative to other +2 
residues in 14-3-3/phosphopeptide structures, we sought to determine if mutating this 
serine to the canonical proline would have a significant effect on Cby’s interaction with 
14-3-3ζ.  The same 7-mer, 13-mer and 18-mer Cby phosphopeptides used previously, but 
now containing the S22P mutation, were used in ITC experiments to determine the 
binding affinity to 14-3-3ζ (Table 2.1, Figure 2.2).  Interestingly, for all S22P Cby 
peptides, the binding affinity was approximately 15-fold tighter for each peptide 
respective to its wild-type counterpart (for 7-mer, KD ~3 versus ~44 µM; for 13-mer, KD 
~1 versus ~15 µM; for 18-mer, KD ~360 nM versus ~5 µM).  The increases in binding 
affinity for the three S22P mutant peptides were all due to more negative ΔH of binding.  
Moreover, the flanking residues within the S22P Cby peptides, like the WT, appear to 
play a role in the interaction as well.  The Cby S22P 18-mer bound ~9 fold tighter than 
the S22P 7-mer, similar to the difference observed between the WT Cby 18-mer and 7-
mer peptides. 
 In numerous crystal structures of 14-3-3 proteins in complex with phosphorylated 
S/T peptides, the conserved K49 (numbering refers to the ζ isoform) side-chain is 
observed forming a hydrogen bond with the phosphate group on pS/pT (illustrated in 
Figure 2.5 with an elucidated 14-3-3ζ/Raf1 structure).  With Cby’s S22 side-chain 
juxtaposed between 14-3-3ζ residues K49 and R56, the K49 side-chain is sterically 
hindered from contacting pS20.  As such, we speculated that the increases in binding 
affinity to 14-3-3ζ observed for the S22P mutant peptides might be the result of the 
favorable contacts between K49 and pS20 facilitated by the proline-induced 
conformational changes.  To test this, a K49A mutation was introduced into 14-3-3ζ and  
55 
 
 
 
 
 
 
Figure 2.5 A comparison of the orientation of 14-3-3ζ's K49 side-chain in the 14-3-
3ζ/Cby and 14-3-3ζ/Raf1 (PDB: 3CU8) complexes 
Cby is represented by the green sticks and Raf1 by the light pink sticks.  K49 in the 14-3-
3ζ/Cby and 14-3-3ζ/Raf1 complexes is shown in yellow and dark pink, respectively. 
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ITC titrations were performed with 18-mer WT and S22P Cby peptides.  Interestingly, 
the data show that the K49A mutation only had a minor effect (WT – 4.9 µM, K49A – 
5.5 µM, ΔΔG ~ 0.1 kcal/mol) on the binding to the WT Cby peptide, however, the mutant 
bound with lower affinity to the S22P Cby peptide compared to the WT 14-3-3ζ (WT – 
0.38 µM, K49A – 1.8 µM, ΔΔG ~ 1.0 kcal/mol) (Table 2.1 and 2.2, Figure 2.6).  
Therefore, K49 appears to at least partially responsible for the enhanced binding affinity 
observed between WT 14-3-3ζ and the S22P Cby peptide. 
 
Figure 2.6 14-3-3ζ K49A ITC thermograms 
ITC thermograms for the A. WT Cby 18-mer and B. Cby S22P 18-mer titrated to 14-3-3ζ 
K49A. 
 
 
2.3.5 Probe for secondary interactions between 14-3-3ζ and Cby 
using NMR spectroscopy 
 The crystal structure of 14-3-3ζ/Cby complex clearly reveals the molecular basis of 
primary interactions between 14-3-3ζ and the non-canonical mode II binding motif within 
Cby.  However, like most of the 14-3-3/phosphopeptide structures available to date, the 
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lack of electron density for residues outside the phosphorylated binding motif of Cby 
hinders our understanding of the secondary interactions in complex formation.  Notably, 
our ITC results showed that the Cby 18-mer (12KTPPRKSA(pS)LSNLHSLDR29) used in 
the crystallographic study has a significantly higher affinity compared to the 7-mer 
(16RKSA(pS)LS22; the minimal 14-3-3 binding motif) for 14-3-3ζ.  However, only 
residues 23NLH25 outside the minimal binding motif were observable in the crystal 
structure.  Of the three, only the L24 side-chain is buried within the interface, projecting 
toward a hydrophobic patch consisting of 14-3-3ζ residues L216 and I217.  Intriguingly, 
immunoprecipitation experiments performed by Li et al.[14] demonstrated that an alanine 
substitution at L24 on Cby abolished binding to 14-3-3ζ.  Our ITC titrations with the Cby 
18-mer comprising the L24A mutation revealed that its interaction with 14-3-3ζ was 
indeed impaired but not abolished, binding approximately 4-fold weaker than the wild-
type peptide with a KD ~21 µM (Table 2.1 and 2.2, Figure 2.2).  To gain a more thorough 
understanding of the secondary interactions between 14-3-3ζ and Cby, we sought to 
determine if there are additional regions in 14-3-3ζ that interact with the Cby 18-mer 
compared to the 7-mer using NMR chemical shift mapping, a powerful technique for 
identifying binding interfaces in solution.  
 Due to the relatively high molecular weight of the 14-3-3ζ dimer (~56 kDa), 
deuterated protein samples were used in our NMR studies.  An initial 1H-15N TROSY-
HSQC spectrum of 14-3-3ζ displayed many well-dispersed resonance signals along with 
a small number of extremely intense peaks (Figure 2.7).  These strong peaks do not 
display any chemical shift changes upon titration of the unlabeled 18-mer Cby peptide, 
indicating that their corresponding residues are not involved in the interaction (Figure 
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2.7).  However, their presence in the 1H-15N TROSY-HSQC spectrum unavoidably 
complicates the spectral analysis by masking many underlying resonances.  We 
speculated that these high intensity resonances originate from 14-3-3ζ’s C-terminal tail, 
which has been shown to be disordered [41].  With this in mind, we have generated the 
14-3-3ζΔC12 construct, which is full-length 14-3-3ζ with the C-terminal 12 residues 
being removed.  The 1H-15N TROSY-HSQC of 14-3-3ζΔC12 overlays almost perfectly 
with that of 14-3-3ζ, except that the highly intense peaks are no longer observable, 
confirming that these resonances originate from the C-terminal tail.  Importantly, ITC 
experiments show that 14-3-3ζΔC12 binds to Cby peptides with almost the same affinity 
as full-length 14-3-3ζ (Table 2.1 and 2.2, Figure 2.8). 
 Backbone resonance assignments for 1HN, 15N, 13Cα and 13Cβ were obtained for 
14-3-3ζΔC12 (Figure 2.9 A).  We were able to assign 82 % of the 1HN and 15N 
resonances of non-proline residues, 81 % of all 13Cα and 81 % of all 13Cβ resonances.  
The presence of weak peaks prevented a higher percentage of resonance assignments.  
The residue-specific secondary structure propensity (SSP) scores using 13Cα/β chemical 
shifts [42] indicate that the protein is, as expected, largely α-helical (Figure 2.9 B). 
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Figure 2.7 1H-15N TROSY-HSQC of 2H/13C/15N 14-3-3ζ in the absence (blue) and 
presence of a 1:1 molar ratio of the Cby 18-mer (red). 
Circled resonances represent the intense signals arising from 14-3-3ζ’s disordered C-
terminal tail.  A zoomed-in view displays the intense signals derived from 14-3-3ζ’s 
disordered C-terminal tail. 
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Figure 2.8 ITC thermograms for 14-3-3ζΔC12 
ITC thermograms for the A. Cby 13-mer and B. Cby 18-mer titrated to 14-3-3ζΔC12. 
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Figure 2.9 Backbone resonance assignment of 14-3-3ζΔC12 
A. 1H-15N TROSY-HSQC spectrum and backbone resonance assignment of 2H/13C/15N 
labeled 14-3-3ζΔC12.  B. Secondary structure propensity (SSP) scores for 14-3-3ζΔC12.  
SSP scores were calculated based upon the 13Cα/β chemical shifts. 
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2.3.6 Mapping the Cby peptides binding regions on 14-3-3ζΔC12 
The nearly complete backbone assignment of 14-3-3ζΔC12 affords an opportunity 
to map the binding regions of different Cby peptides on 14-3-3ζ in a highly efficient 
manner.  The 7-mer and 18-mer Cby peptides were titrated to 14-3-3ζΔC12 in a series of 
NMR experiments to a final molar ratio of 3:1 (peptide:protein) for chemical shift 
mapping (Figure 2.10 A).  When comparing the 1H-15N TROSY-HSQC spectra of 14-3-
3ζΔC12 in the apo and the 7-mer/18-mer Cby bound forms, a large number of chemical 
shift changes as well as peak broadenings are observed.  The chemical shift perturbations 
were calculated for both titration sets and were mapped onto the 14-3-3ζ/Cby structure 
(Figure 2.11 B & C, Figure 2.12 A).  From the generated maps, the residues exhibiting 
the largest chemical shift changes for both peptides are found within helices αC, αE and 
αI, matching well with the binding interface observed in the crystal structure (Figure 2.11 
A).  Additional peaks within the binding cleft were broadened out over the course of the 
titrations.  For the Cby 18-mer titration, these peaks include M121, D124, Y125 and 
A130 within αE, L170, L172, V176 and Y178 within αG, and I217, L220 and R222 
within αI.  Broadened resonances within the binding cleft are similar for the Cby 7-mer 
titration, including F117, M121, D124 and A130 within αE, L170, L172, V176, F177 
and Y178 within αG, and Y211 within αI.  Even though residues that bond with the 
phosphate group of S20 on Cby, R56, R127 and Y128, could not be assigned, residues 
surrounding this basic patch either broaden out (M121, D124, Y125, V176) or exhibit 
large chemical shift changes (V52, G53) as expected.  Large chemical shift perturbations 
or broadened resonances were not observed along the 14-3-3ζ dimer interface for either 
peptide. 
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 Notably, the Cby 18-mer binding interface appears to be larger than that of the 
pCby 7-mer.  Many 14-3-3ζ residues within the loop between αH and αI (204-208), 
along with N-terminal residues of αI (209-215) exhibit larger chemical shift perturbations 
when titrated with the Cby 18-mer compared to the Cby 7-mer (Figure 2.13).  Based on 
the orientation of the peptide, we speculate that this region of 14-3-3 interacts with the C-
terminal (26SLDR29) residues on the Cby 18-mer peptide. 
 Additional NMR titration experiments were performed with the Cby S22P 18-mer 
to compare its binding interface with the WT.  The chemical shift analysis (Figure 2.10 B 
and 2.12 B) and subsequent mapping onto the 14-3-3ζ/Cby structure (Figure 2.11 D) 
revealed a similar interface to that observed for the Cby WT 18-mer.  Interestingly, while 
the resonance signals of some residues in the αH - αI loop and residues within the 209-
215 range in αI shift similarly when titrated with the WT or S22P peptides, the T205, 
L206, E209 and S210 peaks have much smaller shifts when titrated with the Cby S22P 
18-mer.  Having a proline at the +2 position may affect how the downstream C-terminal 
residues interact with this loop region.  
 
 
 
 
 
64 
 
 
 
 
Figure 2.10 NMR titration experiments of 14-3-3ζΔC12 with Cby peptides 
A. 1H-15N TROSY-HSQC spectra of 14-3-3ζΔC12 alone (black) and with 3 molar 
equivalents of the Cby 7-mer (red) and Cby 18-mer (blue).  B. 1H-15N TROSY-HSQC 
spectra of 14-3-3ζΔC12 alone (black) and with 3 molar equivalents of the WT Cby 18-
mer (blue) and Cby S22P 18-mer (blue). 
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Figure 2.11 The mapping of chemical shifts on the crystal structure of the 14-3-
3ζ/Cby complex 
Due to the crowding of some peaks, the chemical shifts of some residues could not be 
confidently traced and were excluded from the analysis.  A. (Above) A monomer of the 
14-3-3ζ/Cby crystal structure interface based on Cby residues (18SApSLSNLH25).  
Residues R56, R127 and Y128 which contact the Cby phosphate group are coloured red, 
residues interfacing the peptide are coloured cyan, and 14-3-3ζ residues coloured 
magenta are found along the 14-3-3 dimer interface.  (Below)  The 14-3-3ζ dimer bound 
to Cby.   B. (Cby 7-mer), C. (Cby 18-mer) and D. (Cby S22P 18-mer). Residues with 
traceable assigned resonances are coloured on a blue – white –yellow gradient (0 ppm to 
0.1 ppm) based on their combined chemical shift [Δω = ((Δδ1H)2 +(0.2*Δδ15N)2)1/2] at a 
3:1 peptide:protein ratio.  Residues coloured in orange represent peaks that broadened out 
to disappearance upon addition of peptide.  Residues R56, R127 and Y128 are coloured 
pink. 
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Figure 2.12 Composite 1HN and 15N chemical shift perturbation analysis 
Composite 1HN and 15N chemical shift perturbation [Δω = ((Δδ1H)2 +(0.2*Δδ15N)2)1/2] 
analysis of 14-3-3ζΔC12 in the presence of three molar equivalents of the A. Cby 7-mer, 
A. + B. Cby 18-mer and B. Cby S22P 18-mer. Due to the crowding of some peaks, the 
chemical shifts of some residues could not be confidently traced and were excluded from 
the analysis. 
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Figure 2.13 Observed chemical shifts for 14-3-3ζΔC12 residues 204-215 
Resonances shown for each residue include the apo state (black), Cby 18-mer bound-state 
(blue) and the pCby 7-mer bound-state (red), at a 3:1 (pCby: 14-3-3ζΔC12) ratio. 
*Residue Y211 is displayed at a 1.25:1 (Cby: 14-3-3ζΔC12) ratio as it broadens out to 
disappearance at a 3:1 ratio with the Cby 7-mer.  The Cby-18-mer bound-state is shown 
in cyan with the 7-mer bound-state in magenta. 
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2.3.7 Cby binds to all human 14-3-3 isoforms 
From pull-down and coimmunoprecipitation experiments, Li et al. [13] found that 
in addition to the 14-3-3ζ isoform, Cby interacts with the ε and η isoforms.  ITC 
experiments were designed to test whether Cby can bind to all human 14-3-3 isoforms 
and to determine whether there are any large differences in affinity across the isoforms.  
The ITC profiles for the Cby 18-mer/14-3-3 isoforms are shown in Figure 2.14 and the 
fitted data are tabulated in Table 2.4 and 2.5.  The Cby 18-mer peptide bound to all seven 
isoforms with a spectrum of high nanomolar to low micromolar affinity, ranging from ~ 
500 nM for the η isoform to ~ 11 µM for the ε isoform.  
2.3.8 14-3-3 phosphomimetic mutations fail to abrogate the 14-3-
3/Cby 18-mer interaction 
Further to the importance of 14-3-3 linker regions in target recognition, Mancini 
et al. [49] suggested that phosphorylation at serine 186 on 14-3-3σ by the c-Jun N-
terminal kinase (JNK) promotes the dissociation of Cby.  Serine 186, located in the αG-
αH linker on 14-3-3σ, along with the corresponding residue on the ζ isoform, S184, were 
each mutated to glutamate as a phospho-mimetic. Their binding to the Cby 18-mer was 
measured by ITC (Figure 2.15, Table 2.4 and 2.5) and no significant difference in binding 
affinity was observed for either mutant. Phosphomimicry may not be enough to promote 
dissociation of the complex. 
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Table 2.4 Thermodynamic parameters of Cby 18-mer binding to all 14-3-3 isoforms 
Thermodynamic parameters for the binding of 12KTPPRKSA(pS)LSNLHSLDR29 Cby 18-mer 
peptide to human 14-3-3 isoforms and mutants at 25°C. 
Isoform na Kdb (10-6 M) ∆Hb (kcal/mol) T∆Sb (kcal/mol) ∆Gb (kcal/mol) 
14-3-3η 0.97 ± 0.00(2) 0.57 ± 0.02 -10.31 ± 0.05 -1.79 -8.53 ± 0.02 
14-3-3γ 0.98 ± 0.00(4) 0.88 ± 0.04 -9.43 ± 0.06 -1.17 -8.27 ± 0.03 
14-3-3β 0.95 ± 0.00(4) 1.45 ± 0.06 -11.56 ± 0.07 -3.61 -7.97 ± 0.02 
14-3-3ζ 0.88 ± 0.00(4) 2.50 ± 0.10 -9.70 ± 0.07 -2.05 -7.65 ± 0.02 
14-3-3ζ S184E 0.98 ± 0.00(4) 1.21 ± 0.05 -7.47 ± 0.04 0.61 -8.08 ± 0.04 
14-3-3θ 0.93 ± 0.01 4.35 ± 0.14 -7.73 ± 0.06 -0.41 -7.32 ± 0.02 
14-3-3σ 0.93 ± 0.01 5.02 ± 0.18 -7.88 ± 0.09 -0.65 -7.23 ± 0.02 
14-3-3σ S186E 0.94 ± 0.00(5) 3.80 ± 0.04 -6.70 ± 0.05 0.69 -7.39 ± 0.06 
14-3-3ε 0.85 ± 0.04 12.92 ± 0.81 -9.14 ± 0.50 -2.47 -6.67 ± 0.04 
a Binding stoichiometry of monomeric 14-3-3 and Cby peptide. 
bKd is the dissociation constant. ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs 
free energy upon binding at T=298.15 K, respectively. 
 
Table 2.5 Duplicate thermodynamic parameters for the binding of Cby 18-mer to 
14-3-3 isoforms 
Thermodynamic parameters for the binding of 12KTPPRKSA(pS)LSNLHSLDR29 Cby peptide to 
human 14-3-3 isoforms and mutants at 25°C obtained using ITC. 
Isoform na Kdb (10-6 M) ∆Hb (kcal/mol) T∆Sb (kcal/mol) ∆Gb (kcal/mol) 
14-3-3η 0.88 ± 0.00(2) 0.46 ± 0.03 -10.73 ± 0.04 -2.08 -8.65 ± 0.03 
14-3-3γ 1.02 ± 0.03 0.63 ± 0.03 -9.67 ± 0.06 -1.21 -8.47 ± 0.03 
14-3-3β 0.90 ± 0.01 2.08 ± 0.11 -11.57 ± 0.11 -3.81 -7.76 ± 0.03 
14-3-3ζ 0.87 ± 0.01 2.85 ± 0.14 -10.06 ± 0.09 -2.49 -7.57 ± 0.03 
14-3-3ζ S184E 1.02 ± 0.00(3) 1.29 ± 0.04 -7.23 ± 0.03 0.80 -8.03 ± 0.03 
14-3-3θ 0.94 ± 0.00(5) 4.44 ± 0.17 -7.64 ± 0.06 -0.34 -7.31 ± 0.02 
14-3-3σ 0.88 ± 0.01 4.29 ± 0.21 -8.34 ± 0.11 -1.02 -7.33 ± 0.03 
14-3-3σ S186E 0.92 ± 0.00(5) 3.63 ± 0.04 -6.67 ± 0.05 0.75 -7.42 ± 0.06 
14-3-3ε 0.80 ± 0.03 10.59 ± 1.05 -9.87 ± 0.54 -3.07 -6.79 ± 0.06 
a Binding stoichiometry of monomeric 14-3-3 and Cby peptide. 
bKd is the dissociation constant. ∆H, ∆S and ∆G are the change in enthalpy, entropy and Gibbs 
free energy upon binding at T=298.15 K, respectively. 
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Figure 2.14 ITC thermograms for Cby 18-mer binding to all 14-3-3 isoforms 
ITC thermograms for phosphorylated Cby 18-mer titrated into the seven human isoforms 
of 14-3-3. A. 14-3-3β B. 14-3-3γ C. 14-3-3ε D. 14-3-3ζ E. 14-3-3η F. 14-3-3θ G. 14-3-
3σ 
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Figure 2.15 ITC thermograms for Cby 18-mer binding to 14-3-3 phosphomimetics 
ITC thermograms for phosphorylated Cby 18-mer titrated into A. 14-3-3ζ S184E and B. 
14-3-3σ S186E. 
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2.4 Discussion 
 The molecular basis of the interaction between 14-3-3ζ and Cby was extensively 
investigated by using a combination of X-ray crystallography, NMR spectroscopy, and 
ITC.  Our ITC results show that even though phosphorylation of Cby-S20 is critical for 
the complex formation (as Cby peptides comprising S20D and S20E phospho-mimetics 
failed to bind to 14-3-3ζ), residues outside the 14-3-3 binding-motif also play an 
important role in the interaction.  This is supported by the finding that a short, 7-residue 
phosphopeptide of Cby comprising the minimal 14-3-3 binding-motif bound 10-fold 
weaker compared to a longer, 18-residue phosphopeptide.  A similar observation was 
made in a recent study of 14-3-3/α-integrin tail complexes, demonstrating that a 30-
residue α4-integrin peptide comprising its 14-3-3-binding motif bound up to 15 times 
tighter to 14-3-3ζ than an 11-residue peptide [40].  Interestingly, in the same study, short 
and long phosphopeptides comprising the 14-3-3 binding motif for the β2-integrin bound 
with nearly the same high affinity, suggesting that secondary interactions from flanking 
residues are likely sequence specific. 
 Another interesting finding from our ITC experiments is that the phosphorylated 
Cby peptides comprising a mutation at the pS + 2 position to the canonical proline (S22P) 
bind ~15 fold tighter than the WT peptides.  Our crystal structure provides molecular 
insight into the target binding specificity of 14-3-3.  Based on available crystal structures 
of various 14-3-3 isoforms in complex with phosphorylated peptides comprising type I or 
type II binding motifs (for example, PDB: 1QJA [31], 1QJB [31], 3MHR [43]), the K49 
(ζ sequence) side chain commonly forms a hydrogen bond with the phosphate group on 
pSer.  However, in the 14-3-3ζ/Cby crystal structure, the side chain of S22 positions 
73 
 
between K49 and R56 of 14-3-3ζ and sterically hinders the interaction between K49 and 
pS20.  Interestingly, introducing K49A mutation to 14-3-3ζ does not affect its affinity for 
the WT Cby peptide, but the binding affinity to the S22P peptide was reduced by ~5 fold.  
From these results, we speculate the S22P mutation of Cby promotes a conformational 
change in the bound state, allowing K49 on 14-3-3ζ to form hydrogen bond with the 
phosphate group on S20.  However, it should be noted that there are examples of peptides 
containing a +2 proline co-crystallized with 14-3-3 proteins where K49 is either not 
making any direct contacts with the ligand (PDB: 4FL5) or it interacts with other residues 
within the phosphopeptides (PDB: 3UAL [44], 4IEA [45]) instead of the phosphorylation 
site.  Additionally, a proline at the +2 position is not absolutely essential for a K49 – 
phosphate group interaction.  This contact is observed in the 14-3-3γ/tyrosine 
hydroxylase structure (PDB: 4J6S [46]) and in the 14-3-3ζ/alpha-4 integrin, which both 
have a leucine at the +2 position.     
 With only 8 of the 18 residues in the Cby 18-mer peptide resolved in the crystal 
structure, it is likely that any secondary contacts made by flanking residues are very 
dynamic.  This is a common issue in the co-crystallization of 14-3-3 proteins and 
peptides.  Typically, only short regions (4-10 residues comprising residues nearby the 
pS/pT) within longer phosphopeptides are resolved.  Because significant secondary 
interactions may be critical to 14-3-3ζ’s interaction with Cby, we elected to pursue NMR 
spectroscopy as a means of further characterizing the complex. 
 Chemical shift analysis of 1H-15N TROSY-HSQC titration experiments, performed 
by titrating the 7-mer and 18-mer Cby peptides into isotopically labeled 14-3-3ζΔC12, 
allowed for chemical shift mapping to reveal any differences in the binding interface 
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between both peptides.  We found that 14-3-3ζ residues 204-215 are involved in the 
interaction with the Cby 18-mer but not the 7-mer.  Based on the orientation of the 
peptide in the crystal structure, this would correspond to the residues C-terminal to the 
pS20, 23NLHSLDR29, making transient contacts with this region of 14-3-3ζ.   Chemical 
shift analysis of the Cby S22P 18-mer bound to 14-3-3ζΔC12 revealed a similar binding 
site to that of the WT 18-mer, however some variability in shifts for residues within the 
204-215 range were observed.  This suggests that the +2 residue can affect how 
downstream C-terminal residues interact with 14-3-3ζ.  A +2 proline is of particular 
interest because while it is most commonly observed bound in a trans conformation (e.g. 
1QJA [31]) it has been observed bound in the cis conformation (e.g. 1QJB [31]).    
 Residues 203-210, corresponding to 14-3-3ζ’s αH-αI linker, have been shown to be 
part of a secondary binding site with another 14-3-3 target [30].  The crystal structure of 
the 14-3-3ζ/phosphorylated-AANAT complex, the only full-length protein to be solved in 
complex with 14-3-3, demonstrates that this linker is used by 14-3-3ζ to bind AANAT, 
highlighted by the 14-3-3ζ residue E208 making a salt bridge with R53 of phosphorylated 
AANAT, located in the globular region of the protein.  Additionally, this linker region 
has been implicated in ligand discrimination between 14-3-3 isoforms [47,48].  For 
instance, the phosphatase Cdc25C can bind to all 14-3-3 isoforms except for σ; however, 
the mutation of divergent residues within 14-3-3σ’s αH-αI linker to those conserved 
across all other isoforms enables the engineered σ to bind Cdc25C [48].  When we tested 
the binding of the Cby 18-mer to all 14-3-3 isoforms, a high nanonmolar to low 
micromolar spectrum of affinities was observed.  The differences in affinity among the 
14-3-3s may be attributed to sequence variations along the αH-αI or αG-αH linkers of 
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the isoforms. There are potentially greater differences in affinity across isoforms in the 
context of full-length Cby.   
 Building on this work, future studies may elucidate how the complex forms in the 
context of full-length Cby.  It is conceivable that two Cby molecules could retain a 
coiled-coil structure while each is bound to 14-3-3ζ (Figure 2.16).  Because of the 
orientation each 14-3-3ζ monomer adopts upon dimerization, the Cby residues lying on 
the C-terminal end of serine 20 will exit the binding interface at opposing ends of the 14-
3-3ζ dimer.  Since the N-terminal residues (1-64) of full-length Cby are disordered [19] it 
is feasible that each bound Cby molecule retains the flexibility necessary to orient itself 
to form a coiled-coil from residues 73-100, as well as to bind to the 88-kDa β-catenin.  
The model (Figure 2.16) is consistent with the results of Li et al.[13], which 
demonstrated that binding of Cby to β-catenin is not interfered by the increased level of 
14-3-3.  We are aware that a Cby dimer binding to the 14-3-3 dimer could presumably 
lead to a stronger interaction between the two molecules than what was reported in this 
study due to avidity.  How the complex ultimately forms, i.e. its stoichiometry and 
conformation, will aid in providing the mechanistic basis by which the two proteins 
recruit β-catenin to form a trimolecular complex and promote β-catenin’s nuclear 
exclusion. 
 Also of interest is the interplay of Cby’s interactions with 14-3-3 and CRM1.  
Cby’s 14-3-3 binding motif is juxtaposed with its nuclear export signal (NES) 
(21LSNLHSLDR29).  Immunoprecipitation experiments by Li et al. [14] revealed that 14-
3-3 enhanced the Cby-CRM1 interaction in a dose-dependent manner.  It was postulated 
that 14-3-3 might induce a conformational change in Cby to expose its NES for CRM1  
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Figure 2.16 The 14-3-3ζ, Cby, β-catenin tripartite complex. 
Model of dimeric 14-3-3ζ bound to two molecules of full-length Cby. The models of two 
full-length Cby proteins have disordered residues 30–73 of the N-terminus and 100–126 
of the C-terminus presented in a highly extended fashion, and are shown forming a 
coiled-coil from residues 73–100. β-catenin (PDB: 2Z6H) is shown with its Cby binding-
site (helix C) in red which then binds along the C-terminus (64–126) of Cby. 
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recruitment.  In doing so, CRM1 could then mediate the nuclear exclusion of Cby.  Our 
crystal structure demonstrates that this mechanism may not be the case.  The consensus 
NES sequence is Φ1(X2–3)Φ2(X2–3)Φ3XΦ4, where Φ represents critical hydrophobic 
residues L, I, V, F or M and X is any amino acid [50,51].  In determined crystal structures 
of CRM1/target complexes, the critical hydrophobic residues are buried in a hydrophobic 
cleft formed by HEAT repeats 11 and 12 of CRM1 [52,53].  The hydrophobic residues on 
Cby’s NES correspond to L21, L24 and L27.  From our 14-3-3/Cby crystal structure, the 
L21 and L24 sidechains are projected toward 14-3-3’s binding cleft, making them 
inaccessible for CRM1.  Residues (26SLDR29) are unobservable in our structure and thus 
their accessibility remains unknown.  However, Li et al. [14] demonstrated that a L27A 
mutation to Cby did not affect the Cby/CRM1 interaction, and showed normal, WT 
subcellular distribution.  Meanwhile, L21A and L24A mutations abolished the interaction 
with CRM1 and led to the nuclear sequestration of Cby. As such, 14-3-3 may need to be 
dissociated from Cby to allow for the CRM1 interaction.  Further cell experiments and 
structural studies of the Cby/CRM1 complex are needed to comprehend how 14-3-3 and 
CRM1 work in concert to promote the cytoplasmic sequestration of Cby. 
 Finally, NMR studies are critical to the characterization of 14-3-3 interactions as 
their interactome is predicted to predominantly consist of disordered targets [27].  The 
backbone resonance assignment of 14-3-3ζ completed in this work therefore will not just 
facilitate the studies of 14-3-3ζ with Cby, it will be invaluable for probing interactions 
between 14-3-3ζ and a continually growing list of protein targets by NMR.  Such studies 
may allow the identification of ligand-binding interfaces on 14-3-3 in an efficient manner 
as illustrated in this work.  Moreover, with 14-3-3ζ over-expression associated with 
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tumour progression and chemoresistance (reviewed in Matta et al. [54]), the protein is an 
attractive therapeutic target in cancer.  With the availability of the backbone resonance 
assignment of 14-3-3ζ, NMR titration can be a quick way to test the binding/determine 
the binding site of small molecule or peptide 14-3-3 inhibitors [55,56].  Similarly, this 
may also be done for a number of recently discovered 14-3-3 protein-protein small-
molecule stabilizers [55,56], which offer an alternative approach to modulating 14-3-3 
activity.   
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Chapter 3  
3 Conformational characterization of the intrinsically 
disordered protein Chibby: Interplay between structural 
elements in target recognition 
3.1 Introduction 
The Wnt/β-catenin pathway, a signaling cascade whose roles include embryonic 
development and stem-cell self-renewal, has been linked to a number of human diseases 
upon its dysregulation, including cancer [1,2,3]. Human Chibby (Cby), an evolutionarily 
conserved protein, plays a critical role in this pathway by functioning as an antagonist of 
the transcriptional co-activator β-catenin, the key mediator of Wnt signaling [4]. Cby 
achieves its antagonistic activity via two mechanisms. First, Cby interacts with β-catenin, 
forming a complex that prevents β-catenin from binding to and activating Tcf/Lef 
transcription factors [4]. Secondly, Cby/β-catenin forms a tripartite complex with 14-3-3 
proteins to promote β-catenin’s export from the nucleus, further suppressing Wnt 
signaling [5,6]. 
Besides binding to β-catenin and 14-3-3, Cby participates in the Wnt signaling 
pathway by interacting with several other partners including nuclear export receptor 
CRM1 [5], importin-α [5,7], and Thyroid Cancer 1 (TC-1, also known as C8orf4) [8,9]. 
In particular, TC-1, which was originally identified as a gene highly expressed in thyroid 
cancer, positively regulates Wnt signaling through its interaction with Cby [10]. By 
competing with β-catenin for binding to Cby, TC-1 enables free β-catenin to up-regulate 
Wnt target genes [9]. Recent studies show that TC-1 is also associated with ovarian 
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carcinoma [11], tongue squamous cell carcinomas [12], and lung cancer [13], all likely 
through the Wnt/β-catenin pathway.  
In addition to these binding partners, Cby interacts with several proteins outside 
of Wnt signaling such as CEP164 [14], NBPF1, clusterin [15], polycystin-2 and GM130 
[16]. Even though numerous Cby interactors have been identified, the molecular details 
of most of these interactions remain largely unknown. It has been suggested that the 
ability of Cby to bind multiple targets is facilitated by its partially disordered nature [17]. 
In our previous work and that of others [7,17], biophysical and biochemical techniques, 
which include circular dichroism (CD) spectropolarimetry, nuclear magnetic resonance 
(NMR) spectroscopy, cross-linking and gel filtration experiments, were used to 
characterize the structure of Cby. The results demonstrated that the N-terminal half of 
Cby is largely unstructured, whereas its C-terminal half is α-helical and harbors a 
predicted coiled-coil domain [7,17]. The coiled-coil domain allows for the self-
association of Cby in solution, where it exists predominantly as a homodimer [7]. These 
distinct structural elements of Cby are important for mediating its interactions with 
various targets. For example, in Wnt/β-catenin signaling, the disordered N-terminus of 
Cby binds to the 14-3-3 proteins (upon phosphorylation at residue 20 by the kinase Akt) 
[5,18] and the nuclear export receptor CRM1 [5], whereas its C-terminal half is 
responsible for binding to β-catenin [4], TC-1 [9], and importin-α [5,7].  
Proteins containing both unstructured regions and coiled-coil motifs are 
widespread. As in the case of Cby, utilization of both types of structural elements may be 
critical to their biological function [19,20,21,22]. For instance, disordered regions can 
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tune the affinity for protein interaction partners [23]. Increasing or decreasing these 
affinities may be accomplished by different mechanisms [23,24].  Examples include 
providing enhanced stability to the protein or its complex [25], as well as disorder-to-
order transitions upon interaction [26] or autoinhibition [27].  In this work, we sought to 
determine how the disordered regions of Cby affect the stability and target recognition of 
its coiled-coil domain. 
NMR spectroscopy is a valuable tool to dissect the structural details and dynamics 
of partially disordered proteins [28,29,30].  However, in the case of Cby, its 
characterization by NMR spectroscopy has proven to be a challenge. Previous work in 
our lab showed that most of the NMR resonances for Cby’s C-terminal half are too broad 
to be observed under non-denaturing conditions, likely due to the monomer/dimer 
conformational exchange or formation of higher oligomeric forms [17]. This behavior is 
not unique to Cby, as severe NMR broadening has been seen in other proteins that are 
comprised of long disordered regions and coiled-coil motifs [31,32,33].   
Hydrogen/deuterium exchange-mass spectrometry (HDX-MS) is another widely 
used technique to analyze protein folding, structure, dynamics, and interactions 
[34,35,36,37,38]. Backbone amide hydrogens within disordered regions will exchange 
rapidly upon D2O exposure, in comparison to residues in well-folded, rigid regions, 
where slow D2O uptake is mediated by conformational fluctuations that lead to transient 
opening of hydrogen bonds. In this work, we combined HDX-MS, NMR spectroscopy, 
CD, and isothermal titration calorimetry (ITC) to investigate the interplay of different 
Cby structural elements during target (TC-1) recognition. 
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3.2 Materials and Methods 
3.2.1 Protein Expression and Purification 
The expression and purification protocols for full-length Cby, CbyΔC20 (deletion 
of the last 20 residues of Cby), N-Cby (residues 1-63) and TC-1 were carried out as 
described previously [8,10,17]. The pET-15b plasmid containing human TC-1 with an N-
terminal His6-tag was a gift from Dr. E. Chua (University of Sydney, Australia) [10]. The 
His-tags remained uncleaved from the recombinant Cby constructs to increase their 
solubility.   
C-Cby (residues 67-126) and Coil-Cby (residues 67-104) were cloned into the 
Gateway destination vector pDEST-HisMBP. The His-MBP fusion constructs were 
expressed in Esherichia Coli (E. coli) BL21(DE3) pLysS in M9 minimal media and 
induced with 0.75 mM isopropyl-β-D-thiogalactopyranoside (IPTG; Bioshop). For pull-
down assays the His-tagged proteins were purified from crude lysate by affinity 
chromatography using Ni-Sepharose 6 Fast Flow beads (Amersham Biosciences). To 
purify C-Cby and Coil-Cby, the His-MBP tag were cleaved by overnight incubation with 
tobacco etch virus (TEV) protease at room temperature in 20 mM Tris-HCl, 50 mM 
NaCl, pH 7.5. The tag-less Cby constructs precipitated out of solution during the 
cleavage and were subsequently re-solubilized in 20 mM Tris-HCl, 100 mM NaCl, 6 M 
Guanidine, pH 7.5. The protein was passed through a Superdex 200 column (GE 
Healthcare) in the same guanidine-containing buffer. For refolding, C-Cby was dialyzed 
immediately into 10 mM ammonium acetate, pH 5.0 while Coil-Cby was first dialyzed 
into 10 mM sodium acetate, 8 M urea, pH 5.0 and later into 10 mM ammonium acetate, 
pH 5.0. All experiments of this work were performed at pH 5.0 as both Cby and TC-1 are 
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soluble at low pH.  All DNA constructs used in this work were sequenced.  Purified 
proteins were analyzed on SDS-PAGE for purity and mass spectrometry analysis ensured 
they were the correct mass.  
3.2.2 Peptide Synthesis 
The Cby peptide comprising its C-terminal 25 residues (CbyC25) was purchased 
from the Tufts University Core facility. The peptide was dissolved and dialyzed in 10 
mM ammonium acetate, pH 5.0 for NMR experiments. 
3.2.3 Hydrogen/Deuterium Exchange – Mass Spectrometry 
HDX-MS of Cby was performed by mixing protein stock solution in a 1:9 ratio 
with D2O-based labelling buffer at pH-meter reading of 5.0. The final protein 
concentration was 2 µM. Aliquots were removed at selected time points ranging between 
1 min and 2 h. These aliquots were quenched at pH 2.4 by addition of HCl on ice, 
followed by flash freezing in liquid nitrogen. Prior to analysis the aliquots were rapidly 
thawed to ~0 °C and injected into a nanoACQUITY HDX/UPLC (Waters, Milford, 
MA)[39] for peptic digestion, trapping, and peptide separation. A peptic cleavage map of 
Cby is provided in Figure 3.1. Deuteration percentages were calculated as 100% × (m – 
m0)/ (m100 – m0) where m is the centroid m/z for the partially deuterated peptide of 
interest, and where m0 and m100 correspond to minimally and fully deuterated controls, 
respectively [39]. 
3.2.4 Circular Dichroism Spectropolarimetry 
CD spectra and thermal melting curves were collected on a Jasco J-810 
spectropolarimeter (Easton, MD). Spectra of the various Cby constructs (0.15 mg/mL to 
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0.30 mg/mL) were collected at 25 °C in 10 mM ammonium acetate, pH 5.0, with 5 
accumulated scans for each construct. For the melting curves, the temperature was 
scanned from 15 °C to 95 °C, with the ellipticity monitored at 222 nm. The analysis 
program CDSSTR included in the DichroWeb online analysis software was used to 
deconvolute the CD spectra [40]. Deconvolution was performed using the SMP180 
(optimized for 190-240 nm) reference set [41]. 
3.2.5 NMR Spectroscopy 
NMR experiments were carried out on a Varian Inova 600-MHz spectrometer 
equipped with xyz-gradient triple resonance probe at 25 °C in 10 mM ammonium acetate 
buffer, pH 5.0. Samples contained 10% D2O and 1 mM 2,2-dimethyl-2-sila-pentane-5-
sulfonic acid (DSS) as an internal standard for chemical shift referencing. Data were 
processed using NMRPipe [42] and analyzed using NMRView [43]. The backbone 
assignment of TC-1 was previously completed by our lab (BMRB accession code: 15141) 
[8]. 
3.2.6 Isothermal Titration Calorimetry (ITC) 
ITC experiments were performed on a VP-ITC instrument (MicroCal) at 25 °C in 
10 mM ammonium acetate, pH 5.0. 8 µL aliquots of 230 µM TC-1 were titrated stepwise 
into the 1.4 mL sample cell containing 20 µM C-Cby. Titrations of TC-1 to buffer and 
buffer to C-Cby revealed negligible heat changes. The dissociation constant (Kd), molar 
binding stoichiometry (n) and the binding enthalpy (∆H), entropy (∆S) and Gibbs free 
energy (∆G) were determined by fitting the binding isotherm to a one-site model with 
MicroCal Origin7 software. Protein concentrations were determined from amino acid 
analysis (Amino Acid Analysis Facility, SickKids, Toronto, ON). 
90 
 
3.3 Results 
3.3.1 Identifying the coiled-coil region of Cby using HDX-MS 
Owing to previous difficulties encountered during NMR-based characterization 
attempts of full-length Cby [17], we resorted to HDX-MS. The primary goal of these 
measurements was to delineate the coiled-coil dimerization domain of Cby. Figure 3.1 
displays the Cby peptic peptides used in the HDX-data analysis while Figure 3.2 shows 
the deuterium uptake curves for these peptides. Deuteration was quasi-instantaneous for 
the N-terminal half of Cby, i.e., deuterium levels of > 90% were observed already for the 
first experimental time point of 1 min. Similarly, residues 102-126, which make up the 
very C-terminal end of Cby, exhibited extremely rapid deuterium uptake. Strong HDX 
protection is observed in peptides that are near (residues 53-59) and within (residues 60-
90) the predicted boundaries of Cby’s coiled-coil domain (residues 68-102) [7,44], with 
nearly no exchange in the range of residues 91-98. 
For visualization of these data, the deuteration percentages were mapped onto a 
structural model of dimeric Cby for t = 60 min (Figure 3.3). In this model, the coiled-coil 
is presented as residues 73-100, corresponding to four turns of heptad repeats. However, 
we should point out that the N-terminal boundary of the coiled-coil domain is not clearly 
defined in our HDX data since only relatively large peptic fragments (60-84 and 60-90) 
were obtained for this region. In contrast, it is clear that the coiled-coil ends around 
residues 98, as the significant protection observed is immediately succeeded by rapid 
deuterium uptake in the 102-111 peptic fragment. For the rest of the model, Cby’s N-
termini and very C-termini (which will be denoted as its C-terminal extension from now 
on) are displayed in a largely extended state. 
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Figure 3.1 Sequence of human Cby and peptides used in HDX-MS data analysis 
Sequence of human Cby and its His tag (lower case, grey colour). Black lines below the 
sequence are the peptic peptides used in the HDX-MS data analysis, and the broken lines 
are peptides originating from solely the His-tag. Colour scheme: negatively charged 
residues in red, positively charged residues in blue, polar residues in green and non-polar 
residues in black. 
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Figure 3.2 HDX kinetics of peptides in Cby 
The 28-residue His-tag and Cby residue numbers are indicated in each panel. Lines are 
bi-exponential fits. Standard deviations of triplicate measurements are shown as error 
bars. 
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Figure 3.3 HDX-MS data of Figure 3.2 mapped onto a structural model of Cby for 
t=60 min 
The 126-residue Cby is shown as a dimer. Residues 1-72 are shown in a highly extended 
state, the coiled-coil is comprised of residues 73-100 and residues 101-126 are displayed 
in a disordered form. The colouring represents a range of deuteration percentages. 
Peptide mapping did not cover the grey regions. 
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3.3.2 The disordered N-terminal half and C-terminal extension of 
Cby 
As identified by HDX-MS, Cby contains two disordered regions of different 
length flanking the coiled-coil motif. We sought to determine whether these two 
unstructured segments have differing effects on the stability of the coiled-coil structure. 
A number of truncated Cby constructs were generated for this purpose (Figure 3.4). First, 
we tested if Cby’s C-terminal extension plays a role in the formation of the coiled-coil by 
truncating the last 20 residues of Cby (CbyΔC20). A CD spectrum of CbyΔC20 in 10 
mM ammonium acetate, pH 5.0 is highly similar to that of full-length Cby (Figure 3.5 A). 
Deconvolution of the spectra using the DichroWeb software [40] gives 30% helical, 21% 
strand and 49% disordered/turn structure for the full-length Cby and 41% helical, 17% 
strand and 42% disordered/turn for CbyΔC20. The data indicate that the C-terminal 20 
residues are not structured and that the helical content of Cby is maintained upon deletion 
of this disordered extension. Notably, the CD spectrum of a synthetic construct 
comprising the C-terminal 25 residues of Cby (CbyC25), shows that the C-terminal 
extension is largely disordered but does have α-helical propensity (deconvolution: 42% 
helical, 12% strand and 46% turns/disordered) (Figure 3.5 C).   
Next, we investigated the effect of C-terminal truncation on the thermal stability 
of the coiled-coil motif. Figure 3.5 B shows the CD thermal denaturation profiles of wild-
type Cby and CbyΔC20. For the full-length Cby, the ellipiticity at 222 nm gradually 
becomes less negative as the temperature increases from 20 to 50 oC, while the signal 
remains steady for the truncated CbyΔC20 over this temperature range. Once the 
temperature reaches ~60 oC, both constructs display a significant increase (becoming less 
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negative) in ellipiticity, signifying the melting of the coiled-coil. A thermal melt of the 
CbyC25 peptide shows a gradual loss of signal at 222 nm in the 20-50 oC range, which 
likely explains the differences between the thermal denaturation profiles of wild-type 
Cby and CbyΔC20 in that temperature range (Figure 3.5 B). 
While the thermal denaturation of the full-length Cby is reversible, as the CD 
spectrum of the protein at 25 oC is identical before and after the melt, CbyΔC20 
precipitates upon denaturation. Also, during optimization of the CbyΔC20 purification 
strategy, we observed that the truncated version tends to aggregate in the presence of 
NaCl at low concentrations (50 mM) while full-length Cby remains soluble in 100 mM 
NaCl up to a protein concentration of 200 µM. Taken together, these observations 
suggest that the C-terminal extension is important for Cby’s solubility, consistent with 
the prevalence of charged side chains in this region (Figure 3.1). 
 An overlay of the 1H-15N HSQC NMR spectra of full-length Cby and 
CbyΔC20 is shown in Figure 3.6. Similar to the full-length protein, only peaks from the 
N-terminal half of CbyΔC20 can be observed in the HSQC spectrum. Consistent with the 
CD data, the NMR spectrum suggests that Cby’s coiled-coil structure remains intact upon 
deletion of the C-terminal extension, rendering the peaks from this region unobservable 
by NMR. Notably, truncation of the C-terminal extension of Cby does not induce 
significant chemical shift changes or intensity attenuation to the signals originating from 
the N-terminal half, indicating that there are no long-range interactions between the N- 
and C-terminal disordered regions of Cby. 
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Figure 3.4 Cby constructs used in this study 
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Figure 3.5 CD spectra and thermal melts of Cby constructs 
A. CD spectra of full-length Cby and Cby∆C20. Displayed spectra are the average of 5 
scans.  B. Thermal melts of full-length Cby and Cby∆C20 monitored using CD at 222 
nm. C. CD spectra of C-Cby, Coil-Cby and CbyC25.  Displayed spectra are the average 
of 5 scans. D. Thermal melts of C-Cby, Coil-Cby and CbyC25 monitored using CD at 
222 nm. 
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Figure 3.6 NMR spectra of full-length Cby and CbyΔC20 
1H-15N HSQC NMR spectrum of full-length Cby (black) overlayed with a 1H-15N HSQC 
of Cby∆C20 (red) (spectra collected at 100 µM). 
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Next, we sought to characterize isolated C-terminal half of Cby in the absence of 
the disordered N-terminus. A CD spectrum reveals that C-Cby (residues 67-126) is 
largely helical (Figure 3.5 C). The deconvoluted procedure reports 64% helical, 3% 
strand and 33% disordered/turn. The [θ]222/[θ]208 ratio is ≈ 1, which is indicative of 
coiled-coil structure [45]. A thermal melt of C-Cby, using CD monitored at 222 nm, 
displays a profile similar to that of full-length Cby, where a broad transition is observed 
between 20 and 70 oC (Figure 3.5 D).  Like full-length Cby, C-Cby could completely 
refold after thermal denaturation. A HSQC spectrum collected for isolated C-Cby only 
contains a few broad peaks, indicating that most of the NMR signals from the coiled-coil 
motif and C-terminal extension in this construct remain largely unobservable (Figure 
3.7). 
After extensive efforts, we managed to purify the coiled-coil domain of Cby 
(Coil-Cby, residues 67-104), despite its significantly lower solubility relative to the other 
constructs. A HSQC spectrum of Coil-Cby has no detectable peaks, while the 
deconvoluted CD spectrum returns 80% helical and 20% disordered/turn and the 
[θ]222/[θ]208 ratio ≈ 1 (Figure 3.5 C).  Its thermal denaturation profile, like all Cby 
constructs comprising the coiled-coil domain, displays a sharp reduction in signal 
between 60-70 oC (Figure 3.5 D). Similar to CbyΔC20, Coil-Cby aggregated upon 
thermal denaturation.   
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Figure 3.7 NMR Spectra of C-Cby 
Overlay of 1H-15N HSQC spectra of C-Cby in the absence (black) and presence (red) of 
TC-1 at a 1:1.5 ratio (C-Cby 100 µM:TC-1 150 µM). 
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3.3.3 Disordered regions of Cby tune its binding affinity to TC-1 
Focusing on the Cby/TC-1 interaction, we next investigated to what extent target 
recognition of Cby is modulated by specific structural elements, i.e., the coiled-coil 
domain, or the N- and C-terminal disordered regions. TC-1 functions as a positive 
regulator of Wnt signaling by competing with β-catenin in binding the C-terminal half of 
Cby [9]. Previous structural characterization of TC-1 by our lab established that the 
predominantly disordered TC-1 contains three regions with α-helical propensity in its C-
terminal half and that these regions are responsible for mediating the interactions with 
Cby [8].  
Upon titration of unlabelled CbyΔC20 to 15N-labelled TC-1 (2:1), decreases in 
peak intensity were observed for residues within TC-1’s C-terminal half (Figure 3.8 B). 
The peaks that displayed intensity losses matched the intensity losses observed when full-
length Cby was titrated to 15N-labelled TC-1 (Figure 3.8 A, C). A titration of the CbyC25 
peptide, which comprises the C-terminal extension, to TC-1 did not result in any intensity 
changes (Figure 3.9 A). Together, these results suggest that the C-terminal extension is 
likely expendable for Cby’s interaction with TC-1. 
Next, the individual halves of Cby, N-Cby and C-Cby, were titrated with 15N-
labelled TC-1. As expected, titrating N-Cby did not induce any changes in the HSQC 
spectrum of TC-1 (Figure 3.9 B). Conversely, titrating C-Cby led to the broadening of 
most TC-1 amide resonances (Figure 3.10 A, B). The drops in peak intensities were most 
severe in the C-terminal half of TC-1, where many signals were broadened beyond 
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detection.  Additionally, titration of unlabelled TC-1 to 15N-labelled C-Cby led to the 
appearance of a number of peaks (Figure 3.7). 
The greater intensity losses observed in the TC-1 spectrum upon titration with C-
Cby suggest that C-Cby binds TC-1 with a higher affinity than the full-length protein. 
This was confirmed by ITC experiments, which revealed that C-Cby binds to TC-1 with a 
Kd of ~ 2 µM (Figure 3.10 C, Figure 3.11 A). On the other hand, the interactions between 
TC-1/full-length Cby and TC-1/CbyΔC20 are too weak to produce discernible enthalpy 
changes with the protein concentrations (which are limited by the proteins’ solubilities) 
used in the ITC experiments (Figure 3.11 B, C).  
Intriguingly, when Coil-Cby was added to TC-1 in a 2:1 ratio, no changes in the 
HSQC spectrum were observed (Figure 3.9 C). The lack of observed binding may be due 
to its potential aggregation at the concentration (~100 µM) used for these NMR 
experiments. Attempts to concentrate the protein to > 200 µM led to the observation of a 
gel-like precipitate, again highlighting the importance of disordered regions for the 
solubility of Cby. 
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Figure 3.8 TC-1/Cby NMR titration experiments 
A. Overlay of 1H-15N HSQC spectra of TC-1 in the absence (black) and presence (red) of 
full-length Cby at a 1:2 ratio (TC-1 60 µM:Cby 120 µM). B. Overlay of 1H-15N HSQC 
spectra of TC-1 in the absence (black) and presence (blue) of Cby∆C20 at a 1:2 ratio 
(TC-1 60 µM:Cby∆C20 120 µM). C. Intensity ratios (I/Io) for assigned TC-1 amide 
resonances in the presence (I) or absence (Io) of either full-length Cby or Cby∆C20. 
Yellow shaded areas correspond to the three regions on TC-1 with high-helical 
propensity as determined by chemical shift analysis [8]. 
 
104 
 
 
 
 
 
 
 
 
 
Figure 3.9 NMR titrations with TC-1/Cby constructs 
A. Overlay of the 1H-15N HSQC spectra of TC-1 in the absence (black) and presence 
(red) of N-Cby at a 1:2 ratio (TC-1:N-Cby). B. Overlay of the 1H-15N HSQC spectra of 
TC-1 in the absence (black) and presence (red) of CbyC25 at a 1:2 ratio (TC-1:CbyC25). 
C. Overlay of the 1H-15N HSQC spectra of TC-1 in the absence (black) and presence 
(red) of Coil-Cby at a 1:2 ratio (TC-1:Coil-Cby). 
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Figure 3.10 TC-1/C-Cby NMR and ITC binding experiments 
A. Overlay of 1H-15N HSQC spectrum of TC-1 in the absence (black) and presence (blue) 
of full-length C-Cby at a 1:2 ratio (TC-1 50 µM:C-Cby 100 µM). B. Intensity ratios (I/Io) 
for assigned TC-1 amide resonances in the presence (I) or absence (Io) of either full-
length Cby (as shown in Figure 3.8) or C-Cby. Yellow shaded areas correspond to the 
three regions on TC-1 with high-helical propensity as determined by chemical shift 
analysis[8]. C. An ITC thermal profile of TC-1 binding to C-Cby. Thermodynamic 
experimental values are displayed. Kd is the dissociation constant ΔH, ΔS and ΔG are the 
change in enthalpy, entropy and Gibbs free energy upon binding at T = 298 K, 
respectively. 
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Figure 3.11 ITC thermograms for binding experiments between TC-1 and Cby 
constructs 
A. A duplicate ITC thermal profile of TC-1 binding to C-Cby in 10 mM ammonium 
acetate.  Thermodynamic experimental values are displayed. Kd is the dissociation 
constant ΔH, ΔS and ΔG are the change in enthalpy, entropy and Gibb free energy upon 
binding at T = 298.15 K, respectively. B. ITC thermal profile of TC-1 binding to full-
length Cby in 10 mM sodium acetate, pH 5.0. C. ITC thermal profile of TC-1 binding to 
CbyΔC20 in 10 mM ammonium acetate, pH 5.0. 
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3.4 Discussion 
The mapping of coiled-coil domains using NMR spectroscopy has proven to be a 
challenge for not only Cby, but also for other partially unstructured proteins such as 
CHOP, Par-4 and NA14 [31,32,33]. For those three proteins, the only observable HSQC 
peaks correspond to residues located in disordered regions. As demonstrated in this study, 
HDX-MS is a valuable alternative technique for deciphering which residues make up 
these coiled-coil domains. 
Cby first exhibits HDX protection in large fragments comprised of residues 60-84 
and 60-90. Our ability to set a defined boundary for the N-terminus of the coiled-coil is 
limited by the size of the peptic fragments produced during online digestion. Meanwhile, 
a peptic fragment comprising residues 85-90 displays further reduced HDX rates while 
residues 91-98 display virtually no deuterium uptake over the course of the experiment. 
These results align well with the predicted coiled-coil region, residues 68-102 [7]. 
The HDX data revealed a previously unrecognized structural feature, i.e., 
considerable disorder in the C-terminal extension of Cby (residues 102-126), where 
deuterium levels around 90% were observed for the earliest time point of t = 1 min. This 
behavior does not necessarily imply that the C-terminal extension is completely unfolded. 
Instead, it is more likely that this region exhibits rapid coil/helix fluctuations. Following 
the standard HDX model [46] one can estimate the average deuteration rate constant as 
kHDX = Kop × kch, where Kop is the coil/helix equilibrium constant, and kch ≈ 7 min-1 is the 
“chemical” exchange rate constant at pH 5. An assumed value of Kop = 0.3 corresponds to 
a deuteration level of 90% for t = 1 min. Thus, our HDX data suggest that the residual 
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helicity of the C-terminal extension could be as high as 77% (considering that a coil/helix 
equilibrium constant of 23/77 yields Kop = 0.3).  Although the C-terminal extension is not 
part of the coiled-coil domain, it is not visible in the HSQC spectra of full-length Cby or 
its C-terminal half (C-Cby). It is likely that the proximity of the C-terminal extension to 
the coiled-coil and the suggested coil/helix fluctuations collectively contribute to signal 
broadening of these residues.  
Our NMR and CD spectroscopy experiments demonstrate that Cby’s C-terminal 
extension is expendable for coiled-coil formation, in good agreement with a yeast two-
hybrid assay that demonstrated full-length Cby could bind to a large Cby fragment 
(residues 60-112), where the C-terminal extension’s last 14 residues are not present [16]. 
However, the absence of the C-terminal extension results in a reduction in Cby’s 
solubility. Importantly, this extension plays a major functional role as it contains Cby’s 
nuclear localization signal, residues 123-126, which binds to importin-α [5].  
From our NMR experiments, Cby’s coiled-coil domain mediates the interaction 
with TC-1. For the Cby/TC-1 interaction, no binding was observed between TC-1 and the 
CbyC25 peptide, while the CbyΔC20 construct was observed to bind TC-1 by NMR 
spectroscopy. Notably, while the coiled-coil is required for the Cby/TC-1 complex 
formation, we failed to detect interactions between Coil-Cby and TC-1 by NMR, possibly 
due to the aggregation of the former at high concentration. Despite remaining α-helical as 
shown by CD spectroscopy, the absence of both disordered ends on Coil-Cby drastically 
reduces the solubility of this domain.  
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The C-Cby construct bound to TC-1 with much greater affinity compared to full-
length Cby.  Our ITC data, based on the calculated molar ratio, suggests that C-Cby binds 
to TC-1 as a dimer.  We speculate that the bound C-Cby dimer likely lies along the 
helical region of TC-1’s C-terminal half.  The difference in affinity for TC-1 between 
full-length and C-Cby may be due to a higher entropic cost of binding for full-length Cby 
compared to C-Cby. Alternatively, the disordered N-terminus of Cby may inhibit the 
interaction by acting as an entropic bristle, that is, an unstructured region that impedes 
surrounding macromolecules via random, thermally driven motions [47]. 
In summary, our HDX-MS data help characterize the structure and dynamics of 
the NMR-invisible C-terminal half of Cby. The data reveal that Cby is comprised of a 
disordered N-terminus, a short coiled-coil and an unstructured C-terminal extension. 
These three structural elements were assessed for their importance to Cby’s interaction 
with the Wnt signaling enhancer TC-1. Our results also provide insight into how Cby’s 
disordered regions and coiled-coil work in concert to assemble higher order protein 
complexes, such as the trimolecular Cby/14-3-3/β-catenin [6] or Cby/clusterin/NBPF1 
complexes [15].  Cby’s N-terminus comprises the binding motifs for a number of binding 
targets, including 14-3-3 protein and clusterin. In the free state, Cby’s N-terminus may 
reduce the affinity for some binding targets that bind to its C-terminal half, as 
demonstrated in this work with TC-1. However, this inhibition may be abrogated if the 
N-terminus is present in a bound state. Such a mechanism may allow for cooperative, 
sequential formation of multi-molecular Cby complexes. 
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Chapter 4  
4 Cby’s coiled-coil domain: Differing binding modes to 
TC-1 and β-catenin 
4.1 Introduction 
The Wnt/β-catenin signaling pathway, activated by the Wnt family of cysteine-
rich glycoproteins, is critical in embryonic development, stem cell control and adult 
tissue homeostasis [1,2,3].  Mutations to the Wnt genes as well as Wnt signaling 
components are associated with various human diseases, including cancer [4,5].  
Activation of the pathway occurs when the Wnt proteins interact with the cellular 
receptors frizzled and lipoprotein receptor-related protein (LRP).  Signaling is relayed 
and transduced to the transcriptional co-activator β-catenin where it translocates to the 
nucleus, interacts with the Tcf/Lef family of transcription factors and induces Wnt 
signaling target genes [6].  When the pathway is turned off, cytosolic β-catenin exists 
within a large protein complex, termed the destruction complex.  This complex is 
comprised of scaffolding proteins (Axin, APC) and a collection of kinases (GSK3β, Ck1) 
that phosphorylate β-catenin [6].  Phosphorylated β-catenin is targeted for ubiquitination 
and subsequent degradation through the proteasome [7]. 
 With aberrant Wnt signaling being implicated in a number of diseases, cellular 
regulation of the Wnt signaling cascade is vital.  Regulation of the key player in the 
pathway, β-catenin, is a focal point, with a number of its binding partners influencing its 
phosphorylation, degradation, cellular localization and ability to interact with the Tcf/Lef 
transcription factors [8,9,10].  One such modulator is the protein Chibby (Cby), an 
antagonist of β-catenin-mediated signaling [11].  Cby’s antagonism is achieved using two 
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mechanisms.  First, it competes directly with the Tcf/Lef transcription factors for binding 
to β-catenin [11] and secondly, in conjunction with the 14-3-3 proteins, promotes the 
cytoplasmic sequestration of β-catenin [12,13].  These two modes of regulation 
effectively suppress Wnt signaling [13].   
 Cby is regulated by a small, disordered protein named thyroid cancer-1 (TC-1) 
[14].  The 106-residue TC-1 received its name when it was identified as a gene 
overexpressed in papillary thyroid cancer [15].  By binding directly to Cby, TC-1 
effectively frees β-catenin to bind to the Tcf/Lef factors and induces transcription of Wnt 
genes [14]. 
 Structurally, the 17.5 kDa Cby is partially disordered, comprising an intrinsically 
disordered N-terminal half, while its C-terminus harbours a coiled-coil motif [16,17].  
These two structural halves of Cby are independently responsible for interacting with the 
protein’s Wnt signaling binding partners.  The disordered N-terminal half comprises 
Cby’s 14-3-3 binding motif and nuclear exportation signal [13], while the C-terminus 
contains the binding sites for β-catenin [11] and TC-1 [14] as well as its nuclear 
localization signal [13]. Cby interacts with the last α-helix on β-catenin (termed the helix 
C) [18], whereas it binds to the C-terminal half of TC-1 [14,19]. 
 The coiled-coil domain promotes the homo-dimerization of Cby and is predicted 
to range from residues 73-102 [16], which is confirmed in our hydrogen-deuterium 
exchange mass-spectrometry study discussed in Chapter 3.  Some cell studies have 
demonstrated the importance of Cby’s dimerization in Wnt signaling.  By mutagenizing 
some of the core leucines (L77, L84, L91, L98) within the coiled-coil region to alanine, 
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Mofunanya et al. [16] demonstrated that Cby’s dimerization could be disrupted.  These 
engineered monomeric Cby mutants were incapable of binding to importin-α, the 
receptor responsible for Cby’s nuclear localization.  However, pull-downs showed that 
monomeric Cby retained the ability to interact with β-catenin and TOPFLASH assays, a 
reporter kit designed to monitor the activation of the Wnt signaling pathway in cultured 
cells [20], showed that these mutants could still repress β-catenin-mediated signaling.  
Conversely, although ITC experiments have shown that Cby interacts with TC-1 as a 
dimer (Chapter 3), whether or not monomeric Cby can interact with TC-1 is unknown. 
 NMR spectroscopy represents a valuable technique in the characterization of 
intrinsically disordered proteins [21,22].  However, analyzing the Cby/β-catenin 
interaction using NMR spectroscopy is challenging due to Cby’s insolubility in buffers at 
physiological pH, where β-catenin is most stable [17].  Moreover, the majority of 
resonances in Cby’s C-terminal half are severely broadened out to disappearance as the 
result of conformational exchange [17].  The large size of full-length β-catenin (88 kDa), 
along with its elongated shape [18], leads to a rapidly decaying NMR signal, making 
typical protein binding NMR experiments using labelled β-catenin unfeasible. 
 To further dissect Cby’s interaction between its coiled-coil domain and β-catenin, 
a series of mutants were designed to either stabilize or destabilize the coiled-coil.  The 
goal of these mutants was to increase Cby’s solubility and to reduce the severe peak 
broadening observed in Cby’s HSQC spectrum, enabling the Cby/β-catenin complex to 
be studied using NMR spectroscopy.  A diagram of Cby’s coiled-coil, represented as 
helical wheels, is displayed in Figure 4.1.  Within the four heptad-repeats of this domain, 
there are four core leucines (L77, L84, L91, and L98) at position d and two asparagines 
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(N81, N88) are buried in the core at position a.  To destabilize the coiled-coil, 
L84A/L98A (Cby-2A) and L77A/L84A/L91A/L98A (Cby-4A) mutants were generated.  
Conversely, to stabilize the coiled-coil, the two asparagines in the hydrophobic core of 
the domain, N81 and N88, were both mutated to leucine (Cby N81L/N88L).  An 
additional construct comprising six mutations (Cby-6mut, 
N81L/N88L/L90R/L93R/I97R/L99E) was designed to strengthen the dimer interface 
while removing the hydrophobic patch on the coiled-coil surface and to promote the 
formation of an electrostatic bridge between residue E99 and K94. 
Our findings demonstrate that the leucine to alanine mutants, Cby-2A and Cby-
4A, have additional peaks in their 1H-15N HSQC spectra compared to Cby-WT but 
remain insoluble at pH ≥7.  However, making these same mutations to recombinant 
constructs comprising only the C-terminal half of Cby (C-Cby residues 67-126) lead to 
drastically increased solubility as well as the appearance of the majority of NMR peaks.  
Critically, these C-Cby mutants retain binding to β-catenin as demonstrated by pull-down 
and NMR titration experiments. 
 These same mutants were tested for binding to TC-1.  Our results demonstrate 
that the destabilizing Cby-2A mutant was incapable of interacting with TC-1.  
Additionally, although Cby N81L/N88L retained an interaction with TC-1, Cby-6mut did 
not.  Collectively, the results suggest Cby interacts with TC-1 as a dimer, with key 
interacting residues present on the surface of the coiled-coil. 
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Figure 4.1 Schematic of Cby's coiled-coil, represented as helical wheels 
Core leucines (position d) are boxed, core asparagines at position a are highlighted in 
purple, and surface-exposed hydrophobic residues are circled.  Figure was taken from 
Supplementary Material provided in the published manuscript by Mokhtazarda et al. 
[17]. 
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4.2 Materials and Methods 
4.2.1 Mutagenesis, Expression and Purification of Recombinant 
Proteins 
All Cby mutants were generated using the QuikChange Multi Site-Directed 
Mutagenesis Kit (Agilent Technologies).  Each mutant was confirmed through DNA 
sequencing.  Expression and purification of full-length Cby-WT, Cby-2A (L84A/L98A), 
Cby-4A (L77A, L84A, L91A, L98A), Cby N81L/N88L and Cby-6mut (N81L, N88L, 
L90R, L93R, I97R and L99E) were performed as previously described for Cby-WT [17].  
Expression and purification of TC-1 was performed as described in [19].  The expression 
and purification protocols for C-Cby-WT, N81L/N88L, 6mut and Coil-Cby-WT (residues 
67-102) (which are expressed as His-MBP fusions) are described in Chapter 3.  The C-
Cby-2A and C-Cby-4A mutants were found to be soluble after TEV cleavage in a buffer 
comprising 20 mM Tris, 50 mM NaCl, pH 7.5.  C-Cby-2A and C-Cby-4A samples, were 
concentrated and exchanged into 20 mM Tris, 50 mM NaCl, 3 M guanidine-HCl, pH 7.5 
and run through a Superdex 200 column (GE Healthcare) in the same buffer comprising 6 
M guanidine-HCl.  Pooled protein fractions were dialyzed into 50 mM sodium phosphate, 
pH 7.0.     
The pET-28a expression vector for β-catenin, consisting of the first armadillo 
repeat to the C-terminal end (residues 138-781) and termed β-catR1C, was generously 
gifted from Dr. Wenqing Xu of the University of Washington [18]. The His-tagged 
proteins were induced for over-expression in E. coli BL21 (DE3) cells, in M9 medium, 
with 1 mM of IPTG upon reaching an O.D.600 of 0.7 at 37 °C.  Cells were grown for 3 
hours at 37 °C before harvesting.  Cells were lysed and loaded onto Ni-NTA beads.  
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Subsequent eluates were incubated with His-tagged TEV overnight at room temperature.  
The cleavage mixture was then loaded onto Ni-NTA beads in 20 mM Tris, 50 mM NaCl 
pH 7.5, with the His-tagged cleaved β-catR1C collected in the flow-through. 
β-catR10C (tenth armadillo repeat to the C-terminus; residues 531-781) was 
inserted for expression into a pDEST17 vector using Gateway Recombination Cloning 
Technology (Thermo Fisher Scientific).  The His-tagged β-catR10C was grown in E. coli 
BL21 (DE3) pLysS cells at 37 °C in M9 medium.  Upon reaching an O.D.600 of 0.7, 
overexpression was induced with 1 mM of IPTG at 22 °C.  Lysed cells were loaded onto 
Ni-NTA beads and elutions were dialyzed into 50 mM sodium phosphate, pH 7.0.  The 
His-tag was not cleaved for solubility purposes. 
All proteins used in this work were analyzed on SDS-PAGE and electrospray 
ionization mass spectrometry for purity and to ensure they were the correct mass. 
4.2.2 Circular Dichroism Spectropolarimetry 
CD spectra and thermal melting curves were collected on a Jasco J-810 
spectropolarimeter (Easton, MD). Spectra of full-length Cby-WT, Cby (N81L/N88L), 
Cby-6mut, Cby-2A and Cby-4A and C-Cby(N81L/N88L), C-Cby-6mut (at 
concentrations ranging from 0.15 mg/mL to 0.30 mg/mL) were collected in a 1 mm 
cuvette at 25°C in 10 mM sodium acetate, pH 5.0 with 5 accumulated scans each.  
Spectra for C-Cby-2A and C-Cby-4A were collected in 50 mM sodium phosphate, pH 
7.0. The program CONTIN included in the DichroWeb online analysis software [23] was 
used to deconvolute the CD spectra. Deconvolution was performed using the SMP180 
(optimized for 190-240 nm) reference set [24,25].   
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For the melting curves of all Cby constructs, the temperature was scanned from 
20 °C to 95 °C, with the ellipticity monitored at 222 nm.  Full-length and C-terminal half 
Cby-WT, Cby N81L/N88L and Cby-6mut were performed at a rate of 1 °C/min and full-
length Cby-2A and Cby-4A were performed at 3 °C/min. 
4.2.3 Pull-down Assays 
For the MBP-Cby fusion pull-down assays, 30 µg of His-MBP fusions (Coil-Cby, 
C-Cby and all C-Cby mutants) in 500 µL were incubated with 30 µL of amylose resin for 
1 hour in protein binding buffer (PBB) (20 mM Tris, 70 mM NaCl, pH 7.5) at room 
temperature.  After washing with two individual 500 µL washes with PBB, 100 µg of β-
catR1C in 500 µL was incubated with the resin in PBB for 45 minutes at room 
temperature.  Beads were washed with 100 µL of PBB followed by an additional 75 µL 
wash of PBB.  Bound proteins were eluted with 50 µL of PBB containing 100 mM 
maltose.  30 µL of the eluted fractions were run on SDS-PAGE. 
4.2.4 NMR Spectroscopy 
NMR experiments were performed on Varian Inova 600 MHz spectrometers 
equipped with xyz-gradient triple resonance probe at 25 oC.  Samples contained 10% 
(v/v) D2O and sodium 2, 2-dimethyl-2-silapentane-5-sulfonate (DSS) was added as an 
internal standard for chemical shift referencing.  Buffers used for each experiment and 
protein concentrations used for titration experiments are described within the figure 
captions.  NMR data were processed using NMRPipe [25] and analyzed using NMRView 
[26]. 
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4.2.5 Peptide Synthesis 
 The Cby peptide comprising its C-terminal 25 residues (CbyC25) was purchased 
from and synthesized at the Tufts University Core facility.  The peptide was dissolved in 
20 mM Tris, 50 mM NaCl, pH 7.5 for ITC experiments. 
4.2.6 Isothermal Titration Calorimetry 
Using a VP-ITC instrument (MicroCal), 0.6 mM of the CbyC25 peptide was 
titrated from the syringe in 10 µL injections into the cell containing 20 µM β-catR1C.  
The titration experiment was run in 20 mM Tris, 50 mM NaCl, pH 7.5 at 25 oC. 
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4.3 Results 
4.3.1 Design of Cby coiled-coil mutants and their effect on the 
protein’s stability 
CD spectra were collected for all mutants to assess their secondary structure 
content and thermal denaturation experiments were used to measure their stability (Figure 
4.2 A-D).  The results for the deconvoluted spectra of all mutants are displayed in Table 
4.1. The WT, N81L/N88L and Cby-6mut constructs share similar percentages of α-helix, 
β-strand and turns-disorder secondary structures.  Conversely, the Cby-2A and Cby-4A 
mutants have a reduced level of α-helical content and an increased level of β-strand 
content relative to Cby-WT. 
Thermal melting curves were collected for each mutant using CD spectroscopy, 
monitored at 222 nm (Figure 4.2 B, D).  Cby-WT, as previously demonstrated in Chapter 
3, displays a gradual loss in signal over the 20 °C – 60 °C temperature range followed by 
a sharper loss of signal starting at approximately 60 °C, signifying the melting of the 
coiled-coil.  Cby-6mut follows a similar pattern as the WT in the 20 °C – 60 °C, 
however, the continued loss of signal starting at 60 °C is much more gradual than the WT 
protein, suggesting that the coiled-coil domain is more stable.  Additionally, like the WT 
protein, Cby-6mut is able to refold properly after its thermal denaturation (data not 
shown).  Interestingly, the N81L/N88L mutant showed almost no change in signal at 222 
nm, suggesting its structure is extremely stable.  Indeed, a CD spectrum of Cby 
N81L/N88L taken at 80 °C shows a nearly identical curve to the protein at 25 °C (Figure 
4.2 A, Table 4.1).  As such, the L90R/L93R/I97R/L99E mutations in the Cby-6mut 
construct, which also contains the N81L/N88L mutations, likely destabilize the coiled-
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coil of the Cby N81L/N88L mutant.  Both the Cby-2A and 4A mutants, which lack a 
coiled-coil structure, showed little reduction in CD signal over the course of the thermal 
melt. 
  1H-15N HSQC spectra of these Cby mutants were collected.  The Cby 
N81L/N88L and Cby-6mut spectra are very similar to that of Cby-WT (Figure 4.3 A, B), 
indicating that only resonances derived from Cby’s N-terminus can be observed in these 
mutants.  HSQC spectra of Cby-2A and Cby-4A show an increase in the number of 
observed peaks compared to Cby-WT (Figure 4.3 C).  For the WT protein, ~ 61 amide 
resonances of 149 non-proline residues (includes His-tag) are detected.  Conversely, ~ 
101 resonances are observed in both Cby-2A and in Cby-4A.  Despite the HSQCs of 
Cby-2A and Cby-4A having more peaks, only 68% of the expected number of peaks are 
observed, suggesting some self-association or conformational exchange may still be 
occurring.  As well, although these new observed resonances are all expected to originate 
from Cby’s C-terminus, it is unknown if some residues have multiple peaks originating 
from monomer and dimer species. While these two mutants display a similar number of 
resonances, the Cby-2A mutant’s spectrum shows more peak crowding and line 
broadening compared to the Cby-4A mutant where the peaks are sharper.  The Cby-4A 
mutant potentially shifts the monomer-dimer equilibrium more toward the monomeric 
state than Cby-2A.  
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Figure 4.2 CD spectra and thermal melts of full-length Cby coiled-coil mutants 
A. CD spectra of full-length Cby-WT, N81L/N88L and Cby-6mut at 25 °C and Cby 
N81L/N88L at 80 °C.  Displayed spectra are the accumulation of 5 scans.  B. Thermal 
melting curves of full-length Cby-WT, N81L/N88L and Cby-6mut using CD at 222 nm.  
C. CD spectra of full-length Cby-2A and Cby-4A.  Displayed spectra are the 
accumulation of 5 scans. D. Thermal melting curves of full-length Cby-2A and Cby-4A 
using CD at 222 nm.  All spectra collected in 10 mM sodium acetate, pH 5.0. 
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Table 4.1 Deconvoluted CD spectra of full-length Cby and C-terminal Cby coiled-
coil mutants 
Unless otherwise specified, all spectra were collected at 25 °C 
  Helix Strand Turns/Disorder 
Full-length Cby 
constructs 
WT 26% 24% 50% 
 N81L/N88L 29% 17% 54% 
 N81L/N88L at 80 
°C  
32% 10% 58% 
 6mut 24% 26% 50% 
 2A 12% 32% 56% 
 4A 17% 31% 52% 
     
C-Cby constructs N81L/N88L 60% 3% 37% 
 6mut 50% 7% 43% 
 2A 8% 36% 56% 
 4A 18% 24% 58% 
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Figure 4.3 1H-15N HSQC NMR spectra of full-length Cby-WT and coiled-coil 
mutants 
A. Cby N81L/N88L (blue) overlayed with WT (black). B. Cby-6mut (red) overlayed with 
WT (black). C. Cby-2A (green) overlayed with Cby-4A (orange).  All spectra were 
collected in 10 mM sodium acetate buffer, pH 5.0. 
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4.3.2 Interactions between TC-1 and Cby mutants 
In Chapter 3, our ITC data suggested that TC-1 bound to dimeric Cby, however it 
is still unclear whether TC-1 can bind to monomeric Cby and which specific residues on 
Cby’s coiled-coil mediate the interaction.  Here we used NMR to investigate the 
interactions of TC-1 with the Cby-2A, Cby-6mut and Cby N81L/N88L mutants.  
Decreases in peak intensities were observed predominantly in TC-1’s C-terminal 
half upon titration of unlabelled Cby N81L/N88L to 15N-labelled TC-1 (2:1) (Figure 4.4 
A, B), similar to what has previously been observed in WT Cby titrations [19].  In 
contrast, titration of Cby-6mut to TC-1 did not lead to any substantial decreases in peak 
intensity (Figure 4.4 C, D).  Collectively, the data demonstrates that although TC-1 
maintained an interaction with the coiled-coil stabilized N81L/N88L mutant, the 
hydrophobic patch on the surface of the coiled-coil, which is mutated in Cby-6mut, may 
mediate Cby’s interaction with TC-1.  However, individual or a combination of mutations 
to residues in this hydrophobic patch (such as L90R, L93R, I97R, without N81 or N88 
mutations) should be designed and tested to confirm their significance in TC-1 complex 
formation.  Next, titration of Cby-2A to TC-1 did not produce any significant changes in 
peak intensities, suggesting that monomeric Cby is unable to bind to TC-1 (Figure 4.4 E, 
F). 
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Figure 4.4 NMR titrations with TC-1 and Cby coiled-coil mutants 
A. Overlay of 1H-15N HSQC spectra of TC-1 in the absence (black) and presence (blue) 
of Cby N81L/N88L at a 1:2 ratio (TC-1 60 µM: Cby 120 µM). B. Intensity ratios (I/Io) 
for assigned TC-1 amide resonances in the presence (I) and absence (Io) of Cby 
N81L/N88L. C. Overlay of HSQC spectra of TC-1 in the absence (black) and presence 
(red) of Cby 6mut at a 1:2 ratio (TC-1 35 µM: Cby 70 µM). D.  I/Io values for assigned 
TC-1 amide resonances in the presence (I) and absence (Io) of Cby-6mut.  E. Overlay of 
HSQC spectra of TC-1 in the absence (black) and presence (green) of Cby-2A at a 1:2 
ratio (TC-1 60 µM: Cby 120 µM). F.  I/Io values for assigned TC-1 amide resonances in 
the presence (I) and absence (Io) of Cby-2A.  All spectra collected in 10 mM sodium 
acetate buffer, 50 mM NaCl, pH 5.0. 
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4.3.3 Structural analysis and stability of mutations to the coiled-coil 
of Cby in constructs lacking the disordered N-terminus 
Characterizing the interaction between Cby and β-catenin using NMR 
spectroscopy is hindered by the two proteins’ buffer incompatibility and by the peak 
broadening observed in Cby’s C-terminal half.  While more resonances are observed in 
the Cby-2A and 4A mutants’ HSQCs, all coiled-coil mutations to full-length Cby 
discussed above are only soluble in buffers of low pH (pH 5) and ionic strength, while 
nearly full-length β-catenin (βcatR1C) is stable in buffers closer to pH 8 with 50-100 mM 
NaCl.  Therefore, we sought to design the same set of mutations on a construct 
comprising the C-terminal half of Cby (C-Cby, residues 67-126), to see if the removal of 
Cby’s disordered N-terminus may help stabilize these mutant proteins in a buffer 
compatible with β-catenin. 
Like the full-length protein, CD spectra and thermal melting curves were 
collected for each C-Cby mutant (Figure 4.5, Table 4.1).  As expected, the C-Cby 
N81L/N88L and 6mut mutants remain folded, containing much higher fractional α-
helical content compared to the full-length mutants in 10 mM sodium acetate, pH 5.  
Additionally, the thermal melting profiles for these two mutants, measured at 222 nm, 
show very similar curves to what was observed in the full-length mutants.  C-Cby 
N81L/N88L displayed very little reduction in signal over the course of the melt.  
Conversely, C-Cby-6mut showed a gradual reduction in signal from 20-65 °C, followed 
by a secondary phase of melting from 70-95 °C.  Although C-Cby-6mut appears to be 
less thermally stable than C-Cby N81L/N88L, it is still remarkably more stable than what 
was observed for C-Cby-WT (see Chapter 3, Figure 3.5 D). 
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The C-Cby-2A and 4A mutants were found to be soluble in sodium phosphate 
buffer, pH 7 upon their refolding (as outlined in the Materials and Methods section).  CD 
spectra of the C-Cby-2A and 4A mutants in 50 mM sodium phosphate, pH 7 show 
drastically reduced α-helical content and increased β-strand content, confirming the 
coiled-coil has been disrupted (Figure 4.5, Table  4.1). 
The HSQCs of all C-Cby mutants were collected to determine whether they 
suffered the same severe line broadening as the C-Cby-WT (see Chapter 3, Figure 3.7).  
The C-Cby N81L/N88L and C-Cby-6mut HSQCs (Figure 4.6, A, B) show multiple weak 
and heavily crowded/clustered peaks characteristic of an oligomerized or aggregated 
protein.  In contrast, the C-Cby-2A and 4A HSQCs, recorded in 50 mM sodium 
phosphate, pH 7, have sharp, dispersed peaks (Figure 4.6, C, D).  Peak detection on the 
C-Cby-2A spectra counts ~ 50 resonances out of the 60 non-proline residues while C-
Cby-4A has ~ 51 of 60 expected peaks.  Similar to what was observed between the full-
length Cby-2A and 4A HSQC spectra, C-Cby-4A has slightly sharper and less crowded 
peaks than C-Cby-2A. 
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Figure 4.5 CD spectra and thermal melts of C-Cby coiled-coil mutants 
A. CD spectra of C-Cby N81L/N88L and 6mut collected in 10 mM Na acetate, pH 5.0. 
Displayed spectra are the accumulation of 5 scans.  B. Thermal melting curves of C-Cby 
N81L/N88L and C-Cby 6mut using CD at 222 nm, collected in 10 mM Na acetate, pH 
5.0.  C. CD spectra of C-Cby 2A and 4A collected in 50 mM sodium phosphate, pH 7.0.  
Displayed spectra are the accumulation of 5 scans. 
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Figure 4.6 1H-15N HSQC NMR spectra of C-Cby WT and C-Cby coiled-coil mutants 
A. C-Cby N81L/N88L. B. C-Cby-6mut. C. C-Cby-2A. D. C-Cby-4A.  C-Cby 
N81L/N88L and 6mut were collected in 10 mM sodium acetate, pH 5.0 and C-Cby-2A 
and 4A were collected in 50 mM sodium phosphate, pH 7.0. 
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4.3.4 Cby’s Interaction with β-catenin 
Previous work has demonstrated the C-terminal half of Cby alone can bind to β-
catenin [11]. Our hydrogen-deuterium exchange (HDX) mass spectrometry results, 
discussed in Chapter 3, revealed that Cby’s C-terminal half contains the coiled-coil 
region and a disordered C-terminal extension ranging from residues 101-126. We 
investigated whether or not the coiled-coil region of Cby is sufficient for binding β-
catenin. A pull-down experiment using amylose resin reveals that an MBP-fused Cby 
construct comprising Cby’s coiled-coil domain (Coil-Cby, residues 67-104) retains the 
ability to bind β-catR1C, while MBP alone does not (Figure 4.7, A).  Additionally, 
isothermal titration calorimetry (ITC) reveals that a synthetic peptide comprising Cby 
residues 102-126 shows no binding to β-catR1C (Figure 4.7, B).  However, this ITC 
result does not rule out very weak binding between the C-terminal extension and β-
catenin.  Alternatively, the C-terminal extension may only participate in the interaction in 
the context of the full-length protein. 
Next, we tested whether the C-Cby coiled-coil mutants could interact with β-
catR1C using an MBP pull-down assay.  Full-length Cby-2A and 4A have already been 
shown to bind to β-catenin using a similar assay using MBP-fusion Cby proteins [16].  
Results of the assay confirm this, as C-Cby-2A pulled-down β-catR1C, while the C-Cby 
N81L/N88L and C-Cby-6mut mutations compromised Cby’s interaction with β-catR1C 
(Figure 4.7, C). 
With the C-Cby-2A construct able to bind to β-catR1C, along with it being 
soluble at physiological pH and having observable amide resonances in its 1H-15N HSQC 
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spectrum, we were able to test the binding of these two proteins using NMR 
spectroscopy.  Titration of β-catR1C to C-Cby-2A at a 0.3:1 ratio showed peak intensity 
loss for some residues, confirming the binding result of the pull-down assay (Figure 4.8). 
 Using NMR spectroscopy to assess the binding between β-catenin and C-Cby-2A 
from β-catenin’s perspective is challenging due to the large size of β-catR1C (~ 70 kDa).  
Therefore, as initial work, we attempted to use a smaller β-catenin construct comprising 
armadillo repeat 10 to the C-terminus (β-catR10C, 28 kDa), which still contains Cby’s 
proposed binding site, helix C on β-catenin [18].  Unfortunately, the HSQC of β-catR10C 
displays less than half of the expected number of amide resonances expected, many of 
which are weak, crowded and dispersed over a narrow 1H chemical shift range (Figure 
4.9, A).  In a previous study, NMR titration experiments by Xing et al. [18] were 
designed to assess whether the disordered C-terminal end of β-catenin interacted with β-
catenin’s armadillo repeats or disordered N-terminal tail.  To do so, they expressed and 
purified the 15N-labelled C-terminal tail (residues, 697-781) of β-catenin and titrated an 
unlabelled construct comprising the armadillo repeats (1-686) (Figure 4.9, B).  The 
group’s collected HSQC spectrum of the C-terminal tail looks extremely similar to what 
we observe in the β-catR10C spectrum, suggesting that no resonances from the armadillo 
repeats in β-catR10C are observed.  Importantly, a CD spectrum of β-catR10C 
demonstrates the protein is folded (deconvolution of spectrum: 33%  α-helix, 21% β-
strand, 46% turns/disordered) (Figure 4.9, C).  An even smaller β-catenin construct, 
perhaps with a truncated C-terminal tail, may be required to assess the complex from β-
catenin’s perspective. 
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Figure 4.7 Cby binding to β-catenin using pull-down assays and ITC 
A. Binding of Cby constructs (C-Cby, Coil-Cby) evaluated by an in vitro pull-down 
assay.  B.  ITC profile of the CCby25 peptide titrated to β-catR1C.  C. Binding of C-Cby-
WT and mutants evaluated by an in vitro pull-down assay. 
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Figure 4.8 NMR titration experiment with C-Cby-2A and β-catenin 
On left: 1H-15N HQSC of C-Cby 2A (black) overlayed with C-Cby 2A in the presence of 
β-catR1C (red) at a 1:0.3 molar ratio (C-Cby 2A: β-catR1C, 45  µM: 15 µM.  On right: 
Zoomed in segment that is boxed in on the left spectrum.  Arrows point to peaks with 
greatest losses in intensity. 
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Figure 4.9 Characterization of β-catR10C 
1H-15N HSQC spectrum of His-tagged β-catR10C in 50 mM sodium phosphate, pH 7.0. 
B. 1H-15N HSQC spectrum of C-terminal β-catenin (residues 687-781) in 20 mM Tris, 
100 mM NaCl, 2mM DTT, pH 7.5 collected and reported by Xing et al. [18]. C. CD 
spectrum (5 accumulated scans) of His-tagged β-catR10C in 50 mM sodium phosphate, 
pH 7.0. 
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4.4 Discussion 
Attempts to analyze the structural mechanisms by which Cby achieves its 
antagonistic role in the Wnt signaling pathway remain hindered by the protein’s 
insolubility.  Additionally, characterizing the protein using NMR spectroscopy is 
hampered by the invisibility of peaks in its C-terminal half, likely due to conformational 
exchange [17].  In this work, we have attempted to use two mutagenesis strategies to 
generate recombinant Cby that is soluble in buffers closer to physiological pH, and that 
may promote the appearance of C-terminal peaks in 1H-15N HSQC spectra.  The first 
strategy was to stabilize the coiled-coil through mutation of core asparagines (Cby 
N81L/N88L), followed by the removal of hydrophobic residues on the surface of the 
coiled-coil (Cby-6mut, N81L/N88L/L90R/L93R/I97R/L99E).  While both of these 
mutants led to a more stabilized coiled-coil relative to WT, both proteins remained 
insoluble at physiological pH and did not produce additional peaks in their HSQC 
spectra.  The second strategy involved breaking the coiled-coil domain using core leucine 
to alanine mutations that have previously been found to produce monomeric Cby.  While 
these Cby-2A (L84A/L98A) and 4A (L77A/L84A/L91A/L98A) mutants successfully 
disturbed the coiled-coil and produced additional resonances in their HSQC spectra, they 
remained highly insoluble.  However, by utilizing the same 2A and 4A mutations to the 
C-terminal half of Cby (C-Cby), we obtained a soluble Cby construct that could be used 
to study the Cby/β-catenin complex using NMR spectroscopy.  
While TC-1 and β-catenin both interact with Cby’s coiled-coil domain [11,14], 
their modes of interaction may be different.  With TC-1, it appears to preferentially bind 
to dimeric Cby as it fails to interact with the monomeric mutant, Cby-2A.  In order to 
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bind to dimeric Cby, TC-1 would have to interact with the surface of the coiled-coil.  
Indeed, while TC-1 maintained an interaction with the N81L/N88L Cby mutant, this 
binding was abolished with Cby-6mut, which has three hydrophobic residues on the 
surface of the coiled-coil mutated to arginine (L90R, L93R, I97R).  Critically, the design 
of Cby mutants with mutations to solely L90, L93 and/or I97R (no mutations to the core 
asparagines, N81L/N88L) should be made to confirm their importance in the TC-1 
interaction.  Conversely, β-catenin was able to bind to monomeric C-Cby-2A as 
demonstrated in a pull-down assay and NMR titration experiment, but was unable to 
interact with C-Cby N81L/N88L and C-Cby-6mut in our pull-down assay.   
The differing modes of interaction in the Cby/TC-1 and Cby/β-catenin complexes 
may be critical to Cby’s regulation in Wnt signaling.  If β-catenin exclusively binds to 
monomeric Cby, then TC-1 will not only antagonize Cby by competing with β-catenin 
for binding to Cby’s C-terminal half, but may also keep Cby in a dimeric state.  
Of note, it is important to point out that being restricted to utilizing pull-down 
assays to characterize the Cby/β-catenin complex is the result of the severe insolubility of 
Cby, hindering our ability to quantitatively assess the strength of the interactions between 
these Cby mutants and β-catenin.  While β-catenin can bind to monomeric Cby, it’s of 
interest to determine whether it binds to the surface exposed residues of Cby’s coiled-coil 
or its core residues.  Also, it is unknown if Cby’s C-terminal extension plays a role in the 
interaction.  Our NMR titration experiment using 15N-labelled C-Cby-2A and unlabelled 
β-catR1C showed reduced peak intensities for a number of residues.  Backbone chemical 
shift assignment of the 1H-15N HSQC spectrum of C-Cby-2A will be critical to determine 
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which residues undergo peak intensity loss and may help in identifying the residues that 
specifically bind to β-catR1C.  Notably, our purification yields only ~ 0.4 mg per L of 
growth in M9 medium, therefore a large scale growth will be required to obtain a 
sufficiently high concentration for 3D NMR experiments.  
Although C-Cby-2A can help provide molecular details of the Cby/β-catenin 
complex, it is unfortunate that the full-length Cby-2A remains insoluble, as the role of 
Cby’s N-terminus in the interaction, if any, cannot be determined.  Although the N-
terminal half of Cby cannot bind to β-catenin on its own, it may still form subsequent 
secondary contacts with β-catenin after the C-terminal half of Cby interacts.  Such a 
mechanism is observed in another inhibitor of β-catenin called ICAT (inhibitor of β-
catenin and Tcf4) [27,28].  ICAT consists of an α-helical N-terminal half and a 
disordered C-terminal half.  ICAT’s antagonism is achieved when its N-terminal helical 
bundle anchors itself into armadillo repeat 12, followed by its unstructured C-terminal 
half interacting around repeats 5-9.  ICAT’s C-terminal half cannot bind to β-catenin 
alone, however, and its N-terminal helical half, although able to bind on its own, cannot 
inhibit Tcf4 binding [29].  As such, the N-terminal half of ICAT must first anchor to β-
catenin, enabling its C-terminal half to subsequently bind and mask the Tcf4 binding site 
(armadillo repeats 2-10).  Seeing as Cby’s C-terminal half anchors to the helix C (and 
possibly armadillo repeat 12) of β-catenin, it is possible Cby’s unstructured N-terminus is 
utilized to mask the Tcf4 binding site. 
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Chapter 5  
5 Summary and Perspectives 
The Wnt signaling antagonist Chibby (Cby) acts on the transcriptional co-
activator β-catenin, preventing its interaction with the Tcf/Lef transcription factors and in 
concert with the 14-3-3 proteins, promotes β-catenin’s cytoplasmic sequestration [1,2].  
The structural mechanisms by which Cby interacts with the Wnt signalling components 
14-3-3 and β-catenin remain elusive, largely due to recombinant Cby’s insolubility, as 
well as its partially disordered structure. Cby harbours a coiled-coil domain in its C-
terminal half while its N-terminal half is unstructured.  These individual halves of Cby 
contain binding motifs for the Wnt signalling components 14-3-3, β-catenin and the Cby 
antagonist, TC-1.  Cby’s N-terminal half contains a 14-3-3 binding motif, whereas its C-
terminal half is responsible for binding to β-catenin and TC-1.  
Cby has proven to be a challenge to work with using NMR spectroscopy, a 
valuable and powerful tool in the analysis of disordered proteins.  In addition to Cby 
requiring low pH (~ 5) and ionic strength to remain soluble, residues within in its C-
terminal half experience severe line broadening in the protein’s 1H-15N HSQC spectra 
[3].  This line-broadening, likely due to conformational exchange of Cby’s coiled-coil, 
not only hinders characterizing Cby by itself, but also the analysis of its protein-protein 
interactions.  Despite these challenges, the work in this thesis provides molecular insights 
into the protein’s interactions with the Wnt signalling components 14-3-3, β-catenin and 
TC-1. 
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5.1 Characterizing the Cby/14-3-3 Interaction 
Upon phosphorylation by the kinase Akt, Cby forms a complex with 14-3-3 to 
facilitate the nuclear export of β-catenin, thereby suppressing Wnt signalling [3].  Using a 
combination of X-ray crystallography, NMR spectroscopy and isothermal titration 
calorimetry, the molecular details of the Cby/14-3-3ζ interaction were revealed.  Using a 
synthetic phosphorylated Cby peptide comprising Cby’s 14-3-3 binding motif, the crystal 
structure of the 14-3-3ζ/phosphorylated Cby complex was solved.  In addition to the 
canonical 14-3-3 binding mode observed in the solved crystal structure, NMR 
spectroscopy and ITC experiments showed that residues flanking Cby’s 14-3-3 binding 
motif are important to the interaction.  First, ITC experiments using phosphorylated Cby 
peptides of different lengths demonstrated that flanking residues contribute to the binding 
affinity.  Second, upon completion of the backbone resonance assignment of 14-3-3ζ, 
NMR titration experiments revealed that residues outside of 14-3-3’s conserved binding 
cleft, namely a flexible loop consisting of residues 203-210, are involved in the Cby 
interaction.  While the structural characterization of the complex focused on the ζ 
isoform of 14-3-3, ITC experiments showed that Cby binds to all seven 14-3-3 human 
isoforms. 
The vast majority of 14-3-3 complexes solved by X-ray crystallography are 
limited to using phosphorylated peptides.  While this may be due to the technical 
challenges of crystallizing protein-protein complexes, the majority of 14-3-3 binding 
partners are thought to be partially disordered [4] and may therefore be non-
crystallizable.  To date, there is only one structure of a nearly full-length binding partner 
(Serotonin N-acetyltransferase or AANAT) in complex with 14-3-3 [5].  The 
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AANAT/14-3-3 complex structure reveals secondary binding contacts (contacts outside 
of the 14-3-3 binding groove, and outside of the binding partner’s 14-3-3 binding motif) 
between AANAT and 14-3-3.  Similar to what was observed in the 14-3-3/Cby complex, 
other structural studies looking at 14-3-3 binding partners, such as integrin [6], have 
demonstrated that residues flanking their 14-3-3 binding motifs contribute to their 
interactions with 14-3-3.  Our completion of the 14-3-3ζ backbone assignment may aid in 
unveiling secondary contacts between 14-3-3 and binding partners that lack discernible 
electron density due to their dynamics in their co-crystallized structures, or for complexes 
that are extremely challenging to crystallize. 
5.2 Elucidating the structural elements of Cby and their 
interplay in target recognition 
 Previous structural analyses of Cby using NMR spectroscopy suffered from 
severe line broadening within the protein’s C-terminal half, hindering the characterization 
of its coiled-coil domain.  In our study described in Chapter 3, we used hydrogen-
deuterium exchange mass spectrometry (HDX-MS) as a complementary technique to 
examine the structural properties of Cby.  Our results reveal three individual structural 
elements on Cby, its disordered N-terminus, the coiled-coil domain and a C-terminal 
unstructured extension consisting of the last ~ 25 residues.  A series of truncation 
constructs were designed to assess the roles each structural element plays in the overall 
stability of Cby as well as their role in binding to the Cby antagonist TC-1.  CD and 
NMR data showed that Cby maintains a coiled-coil structure upon deletion of either 
disordered region.  Additionally, NMR and ITC binding experiments demonstrate that the 
Cby and TC-1 interaction is retained upon deletion of either the N-terminal half or C-
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terminal extension, highlighting that the coiled-coil domain is vital to complex formation.  
Moreover, Cby appears to bind to TC-1 as a dimer.  Interestingly, the C-terminal half of 
Cby alone binds to TC-1 with significantly greater affinity compared to the full-length 
protein.  Our results suggest that Cby’s flanking disordered regions affect the stability of 
the coiled-coil domain and its ability to target binding partners, potentially due to a 
higher entropic cost of binding. 
5.3 Differing binding modes for the Cby/TC-1 and Cby/β-
catenin complexes 
A study by Mofunanya et al. [7] demonstrated that alanine substitutions to two or 
more of the four critical leucines within Cby’s core of its coiled-coil domain (L77, L84, 
L91, L98) were sufficient for eliminating the dimerization of Cby.  Moreover, these Cby 
mutants retained the ability to interact with β-catenin and repress β-catenin-mediated Wnt 
signalling.  Our work described in Chapter 4 focused on determining whether these Cby 
mutants could be utilized to study the Cby/β-catenin complex using NMR spectroscopy, 
with the expectation that the disrupted coiled-coil may improve the solubility of Cby and 
lead to the appearance of C-terminal residue peaks in the protein’s C-terminal half.  Our 
findings show that two Cby mutants with alanine substitutions (L84A/L98A, or 2A, and 
L77A/L84A/L91A/L98A, or 4A) disrupt the coiled-coil in the full-length Cby, but 
remain highly insoluble in buffers close to physiological pH.  However, when the same 
mutations were made to a Cby construct comprising its C-terminal half alone (C-Cby, 
residues 67-126), the mutants were found to be soluble at physiological pH.  
Additionally, the majority of peaks are visible in the C-Cby 2A and 4A 1H-15N HSQC. 
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An NMR titration experiment found that the C-Cby 2A construct binds to β-catenin as 
evidenced by drops in peak intensity for some resonances. 
 Additional mutants were designed along Cby’s coiled-coil and tested for binding 
to TC-1.  It was found that mutating surface exposed hydrophobic residues to arginines 
effectively abolished Cby’s interaction with TC-1. With Cby binding to TC-1 as a dimer, 
it is reasonable to assume residues on the surface of the coiled-coil would mediate the 
interaction with TC-1. 
5.4 Future Directions and Perspectives 
5.4.1 Characterizing the 14-3-3/Cby interaction in the context of 
full-length Cby 
The Cby/14-3-3 interaction has been extensively studied using synthetic 
phosphorylated Cby peptides.  However, questions remain as to how the complex is 
formed when full-length Cby is bound.  First, as the 14-3-3 dimer is able to bind to two 
Cby molecules at the same time, it is of interest to find out if two bound Cby proteins 
could still form a coiled-coil when bound to 14-3-3. The mechanisms for protein 
interactions involving unstructured proteins has largely fallen under a now out-dated 
paradigm of disorder-to-order transitions, as a growing amount of evidence reveals that 
disordered proteins may remain highly dynamic or “fuzzy” in their bound states [8]. 
Thus, although the C-terminal ends of each Cby molecule exit the 14-3-3 binding cleft at 
opposing ends of the 14-3-3 dimer, there could be sufficient length and flexibility in 
Cby’s unstructured N-terminus for the coiled-coil to still form.   Determining the 
particular binding orientation and stoichiometry necessary for the Cby/14-3-3 interaction 
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is critical towards the understanding of Cby-mediated β-catenin cytoplasmic 
sequestration. 
 Several obstacles must be overcome to study this interaction.  First, the in vitro 
phosphorylation of Cby by the kinase Akt must be done in an Akt-active buffer, and one 
which will not cause Cby to aggregate.  As such, successful phosphorylation may require 
an MBP or GST fusion Cby protein.  Alternatively, a recently developed methodology 
allows the incorporation of phosphoserine into proteins in vivo in E. coli [9]. This 
powerful new tool was established by engineering the translational machinery in bacteria 
to enable phosphoserine to be integrated into proteins. This developing method has 
effectively been used to over-express several phosphorylated proteins [9,10,11].   The 
second major hurdle will be finding a compatible buffer for 14-3-3 and phosphorylated 
Cby.  
5.4.2 Cby’s Disordered Ends Modulate Target Binding and 
Applicability of HDX-MS to Other Protein Studies 
An intriguing result from our NMR and isothermal titration calorimetry 
experiments in Chapter 3 showed that the C-terminal half of Cby bound to TC-1 with 
significantly greater affinity than the full-length protein.  This suggest that the free 
unstructured N-terminal domain may auto-inhibit (potentially as an entropic bristle [12]) 
Cby’s binding targets from interacting with the coiled-coil domain.  This begs the 
question that if Cby’s N-terminus is already bound to a protein, for example 14-3-3, 
whether this auto-inhibition may be relieved, allowing the C-terminus to bind to client 
proteins with high affinity.  This mechanism would allow for sequential binding events, 
and would demonstrate cooperativity between Cby’s structural halves. 
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As demonstrated in our HDX-MS experiment on Cby, this technique may be useful in 
characterizing and mapping of coiled-coil domains in other partially disordered proteins.  
Like Cby, NMR studies involving the coiled-coil containing proteins CHOP [13], Par-4 
[14] and NA14 [15] have been troubled by line broadening for residues within their 
coiled-coils.   HDX-MS can provide details on the size and dynamics of their respective 
coiled-coil domains. 
5.4.3 Monomeric Cby and its interaction with β-catenin 
As C-Cby 2A is soluble and its peaks are present in the protein’s HSQC spectrum, 
backbone assignment of this construct, followed by titration experiments may help in 
deciphering which residues within the coiled-coil are responsible for binding to β-catenin.   
Despite the challenges in characterizing the β-catenin/Cby interaction, it has been 
speculated that Cby may antagonize β-catenin in a similar fashion to ICAT [16].  In the 
bound state, an α-helical bundle located in ICAT’s N-terminus anchors within armadillo 
repeats R10-R12 of β-catenin and likely interacts with helix C on β-catenin as well 
[16,17,18].  ICAT’s disordered N-terminus then wraps around armadillo repeats R5-R9.  
The disordered C-terminus is responsible for displacing the Tcf/Lef transcription factors 
whose binding sites extend along repeats R2-R10 [17,19]. This mode of action has been 
referred to as an “anchor-and-kick” mechanism [16]. Intriguingly, despite the disordered 
C-terminal domain of ICAT burying 1700 Å of surface into β-catenin, and forming 
similar contacts in repeats R5-R9 as those seen in APC, Tcf and Lef, it is unable to 
interact with β-catenin in the absence of the N-terminal helical bundle [19].  Moreover, 
while the N-terminal α-helical bundle of ICAT alone maintains binding to β-catenin, it is 
incapable of displacing the Tcf/Lef transcription factors [17].  With regards to the β-
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catenin/Cby interaction, Cby’s C-terminal coiled-coil domain is responsible for binding 
to the helix C of β-catenin and can bind independently of its N-terminal half.  
Conversely, its disordered N-terminus does not bind to β-catenin alone.   
While ICAT and Cby may share similar modes of antagonism, Cby’s dimerization 
represents an additional layer of complexity.  Mutations to monomerize Cby retain the 
ability to bind to β-catenin, however whether Cby can interact in a dimeric state and what 
effect this may have on its effectiveness as a Wnt signaling antagonist must still be 
elucidated. 
5.5 Conclusion 
The coexistence of intrinsic disorder and coiled-coil domains is found throughout the 
proteome.  Elucidating the structural mechanisms by which Cby interacts with itself, β-
catenin, 14-3-3 and TC-1 not only provides insight into its role as an antagonist in the 
Wnt signalling pathway, but offers increased understanding of how dual-module proteins 
consisting of intrinsic disorder and coiled-coil domains function as hubs in signalling 
cascades linked to human disease. 
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